Oral products
A solid oral product combining caffeine, B vitamins, and taurine, optionally with ginseng or vitamin C, addresses the need for effective energy enhancement by providing rapid and sustained energy boosts with reduced side effects, suitable for chewable consumption.
Patent Information
- Application Number
- JP2025519741
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2023-01-06
- Filing Date
- 2023-10-06
- Publication Date
- 2026-11-19
- Estimated Expiration
- 2043-10-06
AI Technical Summary
There is a need for oral products that can deliver active ingredients in an enjoyable and effective form to enhance mental and physical energy levels, while minimizing side effects and providing rapid onset of benefits.
A solid oral product comprising a combination of caffeine, a combination of B vitamins (including at least vitamin B2, B3, B6, B9, and B12), and taurine, optionally with additional ingredients like ginseng or vitamin C, is formulated with binders and extenders such as sugars or sugar alcohols, processed to create a chewable form.
The product provides rapid and sustained increases in mental and physical energy, enhances cognitive abilities, and reduces fatigue, with safe pharmacokinetics and reduced side effects, offering a convenient and enjoyable method of consumption.
Smart Images

Figure 0007954286000002 
Figure 0007954286000003 
Figure 0007954286000004
Abstract
Description
TECHNICAL FIELD
[0001] The present disclosure relates to oral products, processes for manufacturing the oral products, and uses of the oral products. BACKGROUND ART
[0002] The present disclosure relates to products and compositions intended for human use. The products are configured for oral use and deliver substances such as flavors and / or active ingredients during use.
[0003] Products that are easy to administer orally and can provide beneficial effects on specific mood states of humans or animals have become popular in recent years. For example, confectionery-type products (e.g., gummies or lozenges) containing vitamins or other mood-enhancing active substances provide a convenient and comfortable mode of administration for such active ingredients. Other convenient modes of administration are foods and beverages, such as energy drinks. Such products may comprise active ingredients delivered to a user to elicit a biological response in the user that may enhance the user's physical or mental performance.
[0004] Beverages containing theanine and caffeine are described in U.S. Patent No. 5,780,086 and U.S. Patent No. 6,268,009. More recently, European Patent No. 1819241 describes beverages containing theanine and caffeine in a ratio of 5:1 to 1:1.5. Other beverages such as chamomile tea and other herbal teas are consumed by some users to aid sleep and relaxation.
[0005] It is desirable to provide an oral product configured for oral use, which can deliver active ingredients to consumers in an enjoyable and effective form, for example in the form of a solid chew. SUMMARY OF THE INVENTION
[0006] This disclosure generally provides products configured for oral use, comprising a combination of active ingredients, at least one binder and at least one sugar, or at least one sugar alcohol, or a combination of at least one sugar and at least one sugar alcohol. The oral products are solid and may be in a form suitable for oral use, such as a chewable form, such as a soluble chew or lozenge.
[0007] According to some embodiments described herein, a solid oral product is provided comprising a combination of active ingredients, at least one binder, and at least one extender selected from the group consisting of sugar alcohols, or sugars, or combinations of at least one sugar alcohol and at least one sugar, wherein the combination of active ingredients comprises (i) caffeine, (ii) a combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12, and (iii) taurine.
[0008] According to some embodiments described herein, (a) The step of contacting at least one binder with at least one sugar, or at least one sugar alcohol, or a combination of at least one sugar and at least one sugar alcohol, and optionally adding water. (b) A step of heating a mixture of a binder, sugar alcohol and / or sugar, and optionally water, (c) The step of adding (i) caffeine, (ii) a combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) a combination of active ingredients including taurine, A process for preparing an oral product is provided, comprising the step of (d) solidifying the obtained mixture to obtain an oral chewable product.
[0009] According to some embodiments described herein, the use of a combination of active ingredients for increasing alertness and / or energy levels in humans or animals is provided, the combination of active ingredients comprising (i) caffeine, (ii) a combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) taurine.
[0010] According to some embodiments described herein, the use of a combination of active ingredients for increasing the mental and / or physical energy of a human or animal is provided, the combination of active ingredients comprising (i) caffeine, (ii) a combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) taurine.
[0011] According to some embodiments described herein, the use of a combination of active ingredients for increasing the cognitive abilities of a human or animal is provided, the combination of active ingredients comprising (i) caffeine, (ii) a combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) taurine.
[0012] According to some embodiments described herein, a chewable solid oral product is provided comprising a combination of active ingredients, at least one binder, and at least one extender selected from the group consisting of sugar alcohols, or sugars, or combinations of at least one sugar alcohol and at least one sugar, wherein the combination of active ingredients comprises (i) caffeine, (ii) ginseng, and (iii) taurine.
[0013] According to some embodiments described herein, a chewable solid oral product is provided comprising a combination of active ingredients, at least one binder, and at least one extender selected from the group consisting of sugar alcohols, or sugars, or a combination of at least one sugar alcohol and at least one sugar, wherein the combination of active ingredients comprises (i) caffeine, (ii) at least one vitamin B selected from the group consisting of vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12, and (iii) ginseng.
[0014] According to some embodiments described herein, a chewable solid oral product is provided comprising a combination of active ingredients, at least one binder, and at least one extender selected from the group consisting of sugar alcohols, or sugars, or a combination of at least one sugar alcohol and at least one sugar, wherein the combination of active ingredients comprises (i) caffeine, (ii) at least one vitamin B selected from the group consisting of vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) taurine and (iv) vitamin C.
[0015] In a preferred embodiment, each of the oral products of the above embodiments may be provided in the form of a soluble tube.
[0016] These and other features, aspects, and advantages of the Disclosure will become apparent upon reading the following detailed description. The Invention includes any combination of two, three, four, or more of the embodiments described herein, whether such features or elements are expressly combined in the description of the particular embodiments herein, and any combination of two, three, four, or more features or elements described herein. The Disclosure is intended to be read in whole so that, in any of its various aspects and embodiments, any separable feature or element of the disclosed Invention should be considered to be intended to be combinable unless the context clearly indicates otherwise.
[0017] For ease of reference, these and further aspects of the invention are discussed here under appropriate section headings. However, the teachings under each section are not necessarily limited to each specific section.
[0018] As described above, the aspects of this disclosure have been explained using the general terms mentioned above. The attached drawings are provided for illustrative purposes only and should not be construed as limiting the disclosure.
[0019] In all figures, the dashed line represents the placebo (3 tubes), CP represents a commercially available energy product, X2 represents the two tubes and one placebo tube of Example 5, and X3 represents the three tubes of Example 5.
[0020] Next, embodiments of the present invention will be described simply by reference to the attached drawings. [Brief explanation of the drawing]
[0021] [Figure 1] This graph shows the results of a study on cognitive accuracy (RVIP) after ingestion of the oral product (2 chews and 3 chews) of Example 5, compared to a placebo and a commercially available energy product. In this figure, A represents the placebo (3 chews), B represents the commercially available energy product (2 chews) and placebo (1 chew), C represents Example 5 (2 chews) and placebo (1 chew), and D represents Example 5 (3 chews). Letters (e.g., "AB") indicate a significant change from the corresponding product. [Figure 2]This graph shows the results of mental arithmetic (sequential subtraction of 7) after ingesting the oral product of Example 5 (2 chews and 3 chews), compared to a placebo and a commercially available energy product. In this figure, A represents the placebo (3 chews), B represents the commercially available energy product (2 chews) and placebo (1 chew), C represents Example 5 (2 chews) and placebo (1 chew), and D represents Example 5 (3 chews). The letters (as in Figure 1) indicate a significant change from the corresponding product. [Figure 3] This graph shows the overall cognitive scores measured by a composite score of RVIP, NWM, consecutive subtractions of 3, and consecutive subtractions of 7 after taking the oral product (2 chews and 3 chews) of Example 5, compared to a placebo and a commercially available energy product. In this figure, A represents the placebo (3 chews), B represents the commercially available energy product (2 chews) and placebo (1 chew), C represents Example 5 (2 chews) and placebo (1 chew), and D represents Example 5 (3 chews). The letters indicate a significant change from the corresponding product. [Figure 4] This graph shows the level of alertness measured by VAS after ingestion of the oral product (2 chews and 3 chews) of Example 5, compared to a placebo and a commercially available energy product. In this figure, A represents the placebo (3 chews), B represents the commercially available energy product (2 chews) and placebo (1 chew), C represents Example 5 (2 chews) and placebo (1 chew), and D represents Example 5 (3 chews). Letters indicate a significant change from the corresponding product, and ** indicates the first epoch jump at 20 minutes. [Figure 5] This graph shows the physical energy measured by VAS after ingestion of the oral product (2 chews and 3 chews) of Example 5, compared to a placebo and a commercially available energy product. In this figure, A represents the placebo (3 chews), B represents the commercially available product (2 chews) and placebo (1 chew), C represents Example 5 (2 chews) and placebo (1 chew), and D represents Example 5 (3 chews). The letters indicate a significant change from the corresponding product. [Figure 6] This is a graph showing the degree of fatigue measured by VAS after ingestion of the oral product of Example 5 (2 chews and 3 chews), compared with a placebo and a commercially available energy product. In this figure, A represents the placebo (3 chews), B represents the commercially available product (2 chews) and the placebo (1 chew), C represents Example 5 (2 chews) and the placebo (1 chew), D represents Example 5 (3 chews), and the characters indicate significant changes from the corresponding product. [Figure 7] This is a graph showing stimulation measured by VAS after ingestion of the oral product of Example 5 (2 chews and 3 chews), compared with a placebo and a commercially available energy product. In this figure, A represents the placebo (3 chews), B represents the commercially available product (2 chews) and the placebo (1 chew), C represents Example 5 (2 chews) and the placebo (1 chew), D represents Example 5 (3 chews), and the characters indicate significant changes from the corresponding product. [Figure 8] This is a graph showing physical tremor measured by VAS after ingestion of the oral product of Example 5 (2 chews and 3 chews), compared with a placebo and a commercially available energy product. In this figure, A represents the placebo (3 chews), B represents the commercially available product (2 chews) and the placebo (1 chew), C represents Example 5 (2 chews) and the placebo (1 chew), D represents Example 5 (3 chews), and the characters indicate significant changes from the corresponding product. [Figure 9] This is a graph showing overall mood maintenance measured by POMS after ingestion of the oral product of Example 5 (2 chews and 3 chews), compared with a placebo and a commercially available energy product. In this figure, A represents the placebo (3 chews), B represents the commercially available product (2 chews) and the placebo (1 chew), C represents Example 5 (2 chews) and the placebo (1 chew), D represents Example 5 (3 chews), and the characters indicate significant changes from the corresponding product. [Detailed Description of the Invention]
[0022] It is to be understood that the present invention is not limited to the specific configurations, process steps, and materials disclosed herein, as such configurations, process steps, and materials may vary to some extent. Since the scope of the present invention is limited only by the appended claims and their equivalents, it is also to be understood that the terminology used herein is used for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0023] As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. References to "% dry weight" or "on a dry weight basis" refer to weights based on dry components (i.e., all components excluding water). References to "wet weight" refer to the weight of a product or composition including water. Unless otherwise specified, references to "weight percent" (or "% by weight") of a product or composition reflect the total wet weight of the product or composition (i.e., including water).
[0024] As used herein, unless otherwise stated, the term "about" modifying the amount of an ingredient in an oral product of the present invention or used in a method of the present invention refers to variations in numerical quantities that may occur, for example, through typical measurement and liquid handling procedures used to make concentrates or use solutions in the real world, through inadvertent errors in these procedures, through differences in the manufacture, source, or purity of the ingredients used to make the oral product or carry out the method. The term "about" also encompasses amounts that differ due to different equilibrium conditions for a product or composition resulting from a particular initial mixture. Whether or not modified by the term "about", the claims include equivalents to the quantities.
[0025] Oral product As described herein, a solid oral product is provided comprising an active ingredient, at least one binder, and at least one bulking agent selected from the group consisting of a sugar alcohol, or a sugar, or a combination of at least one sugar alcohol and at least one sugar, wherein the combination of active ingredients comprises (i) caffeine, (ii) a combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12, and (iii) taurine.
[0026] Oral products are constructed for oral use and therefore for insertion into the user's mouth (i.e., oral cavity). In this specification, unless otherwise stated, the term “oral” in relation to a product refers to a product that, in normal use, is suitable to be ingested or placed somewhere in the user’s oral cavity. For example, a product may be placed in the mouth and may be chewed in the mouth, for example, in the form of chews or chewing gum. In a preferred embodiment, the product is in the form of chews rather than chewing gum.
[0027] The ranges provided herein offer preferred amounts of each component. Each of these ranges, alone or in combination with one or more other component ranges, can provide preferred embodiments of the present invention.
[0028] Combination of active ingredients The products disclosed herein contain active ingredients.
[0029] The active substances used herein may be physiologically active materials intended to achieve or enhance a physiological response. These active substances may be selected from, for example, nutritional supplements, nootropics, and psychotropic drugs. They may be naturally occurring or obtained synthetically.
[0030] The combination of active ingredients includes suitable active ingredients that evoke a biological response in humans or animals. The active ingredients used herein may be physiologically active materials, which are materials intended to achieve or enhance a physiological response.
[0031] According to one aspect of the present invention, the combination of active ingredients comprises at least (i) caffeine, (ii) a combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) taurine.
[0032] Each active ingredient may be present in a suitable amount to provide the desired biological response in human animals. The inventors have found that certain combinations of active ingredients contained in the oral product provide a rapid onset of mental and / or physical energy. The combinations of active ingredients have been found to provide users with short-term, medium-term, or long-term enhancements of mental and / or physical energy. In particular, certain combinations of active ingredients in the oral product have been found to increase mental energy (i.e., improve cognitive ability, increase energy (arousal, excitability), or reduce mental fatigue and increase the consumer's motivation to perform mental tasks) and increase physical energy (i.e., improve endurance and stamina). The inventors have found that certain combinations of active ingredients of the present invention can improve energy levels over short or sustained periods. Increased energy levels can also increase feelings of confidence, motivation, joy, and excitement, as well as the user's overall feelings of enjoyment and enthusiasm. The inventors have also found that improvements in cognitive ability are present for at least 90 minutes after ingestion. The inventors have further found that the dosage can be adjusted to optimize support for increasing mental and / or physical energy.
[0033] It has also been found that the combinations of active ingredients described herein can provide safe products with desirable pharmacokinetics (Tmax, Cmax, half-life), bioavailability, and metabolism.
[0034] Caffeine is a central nervous system stimulant. Caffeine (1,3,7-trimethylxanthine) is a bitter-tasting alkaloid found naturally in various plant species, including tea leaves, cola nuts, cocoa, guarana, and coffee beans. Upon ingestion, caffeine is metabolized via the cytochrome p450 enzyme system in the liver, allowing it to enter all body tissues and cross the blood-brain barrier. Caffeine can be used to enhance alertness, attention, cognitive abilities, and physical performance.
[0035] Caffeine may be included as a natural stimulant, meaning that it is of natural origin. “Naturally originated” means that the caffeine is in a form purified outside of its natural (e.g., plant) matrix. For example, caffeine can be obtained by extraction and purification from a plant source (e.g., tea). Alternatively or additionally, caffeine may be provided in a synthetic form, i.e., obtained by chemical synthesis. Caffeine may be provided in the form of an extract or a powder (e.g., a powder extract). For example, caffeine may be included in the form of a green tea powder extract or a black tea powder extract. Caffeine may also be provided in the form of a guarana seed powder extract. In some embodiments, caffeine exists in an encapsulated form. An example of encapsulated caffeine is Vitashure®, available from Balchem Corp., 52 Sunrise Park Road, New Hampton, New York, USA (10958).
[0036] Caffeine may be present in any preferred amount, such as at least about 0.001% by weight, at least about 0.01% by weight, or at least about 0.1% by weight of the oral product. In some embodiments, caffeine may be present in an amount of about 20% by weight or less, about 10% by weight or less, about 5% by weight or less, or about 1% by weight or less of the oral product.
[0037] Caffeine may be present in an amount of about 0.01% to about 20% by weight of the oral product. In some embodiments, caffeine may be present in an amount of about 0.01% to about 10% by weight of the oral product. Preferably, caffeine may be present in an amount of about 0.1% to about 5% by weight of the oral product.
[0038] In some embodiments, caffeine is present in an amount of about 0.01% to about 4% by weight of the oral product, for example, about 0.05% to about 3% by weight of the oral product, for example, about 0.1% to about 2.5% by weight of the oral product, for example, about 0.15% to about 2% by weight of the oral product, for example, about 0.2% to about 1.5% by weight of the oral product, for example, about 0.25% to about 1% by weight of the oral product. In some preferred embodiments, caffeine may be present in an amount of about 0.5% to about 1% by weight of the oral product.
[0039] The combination of active ingredients further includes a combination of B vitamins, at least vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12.
[0040] The term "B vitamins" refers to a group of eight water-soluble vitamins that affect cellular functions, such as cellular metabolism and red blood cell synthesis. B vitamins act as coenzymes in a significant proportion of enzymatic processes for cellular physiological functions. Generally, B vitamins can be divided into two categories: those that act as coenzymes in catabolic reactions (resulting in energy production) and those that act as coenzymes in anabolic reactions (resulting in enhanced brain function).
[0041] B vitamins are thought to play a role in brain function and energy production.
[0042] The eight water-soluble B vitamins are vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B5 (pantothenic acid or its salt, e.g., calcium pantothenate), vitamin B6 (pyridoxine hydrochloride), vitamin B7 (biotin), vitamin B9 (folate or folic acid), and vitamin B12 (cyanocobalamin). Vitamins B2, B3, B6, B9, and B12 have been found to aid in anabolic metabolism and enhance brain function. Vitamins B1, B2, B3, B5, and B7 have been found to aid in catabolic metabolism and increase energy levels.
[0043] In a preferred embodiment, the oral product contains all five B vitamins that aid in anabolic metabolism. In other words, according to the first embodiment, the combination of active ingredients includes a combination of vitamins B2, B3, B6, B9, and B12. It has been found that including at least these B vitamins can reduce perceived physical and mental fatigue and enhance psychological and cognitive function. Each of these B vitamins may contribute to reducing lethargy and fatigue, and including all five B vitamins may produce a synergistic effect in this regard.
[0044] In some embodiments, the vitamin B group combination consists of all anabolic vitamins, i.e., combinations of vitamins B2, B3, B6, B9, and B12.
[0045] In some embodiments, the vitamin B group combination further includes at least one catabolic vitamin B group selected from the group consisting of vitamin B1, vitamin B5, vitamin B7, and combinations thereof.
[0046] The ratio of the total amounts of vitamins B6, B9, and B12 to the total amounts of vitamins B2 and B3 may be approximately 2:1 to approximately 1:2, or approximately 1:1 to approximately 1:2. Alternatively, the ratio of the total amounts of vitamins B6, B9, and B12 to the total amounts of vitamins B2 and B3 may be approximately 2:1 to approximately 1:20, or approximately 1:1 to approximately 1:15.
[0047] The amount of B vitamins contained in the composition may be any amount suitable for providing the desired effect while also offering a product that is safe to consume and has reduced side effects.
[0048] The total amount of B vitamins included in the combination may be any suitable amount to provide the desired effect of enhancing brain function. In some embodiments, the total amount of B vitamins (e.g., the total amount of a combination of vitamins B2, B3, B6, B9, and B12) may be at least about 0.01% by weight of the oral product, preferably at least about 0.1% by weight. For example, the total amount of B vitamins may be about 0.01% to about 5% by weight of the oral product, preferably about 0.1% to about 1% by weight. For example, this amount may be about 0.1% to about 0.5% by weight of the oral product, or about 0.1% to about 0.25% by weight of the oral product.
[0049] If present, the total amount of catabolic B vitamins (i.e., the total amount of the combination of vitamins B1, B5, and B7) may be at least about 0.0001% by weight of the oral product, preferably at least about 0.001% by weight, and more preferably at least about 0.01% by weight. For example, the total amount of catabolic B vitamins may be about 0.001% to about 1% by weight, or about 0.01% to about 0.5% by weight of the oral product.
[0050] In some embodiments, vitamin B2 may be present in an amount of about 1% to about 20% by weight of the total amount of B vitamins in the oral product. For example, vitamin B2 may be present in an amount of about 5% to about 15% by weight of the total amount of B vitamins in the oral product.
[0051] In some embodiments, vitamin B3 may be present in an amount of about 20% to about 80% by weight of the total amount of B vitamins in the oral product. For example, vitamin B3 may be present in an amount of about 40% to about 70% by weight, and preferably about 40% to about 50% by weight of the total amount of B vitamins in the oral product. Alternatively, vitamin B3 may be present in an amount of about 30% to about 80% by weight, and preferably about 50% to about 80% by weight of the total amount of B vitamins in the oral product.
[0052] In some embodiments, vitamin B6 may be present in an amount of about 1% to about 15% by weight of the total amount of B vitamins in the oral product. For example, vitamin B6 may be present in an amount of about 5% to about 10% by weight of the total amount of B vitamins in the oral product.
[0053] In some embodiments, vitamin B9 may be present in an amount of about 1% to about 15% by weight of the total amount of B vitamins in the oral product. For example, vitamin B9 may be present in an amount of about 1% to about 10% by weight of the total amount of B vitamins in the oral product.
[0054] In some embodiments, vitamin B12 may be present in an amount of about 1% to about 40% by weight of the total amount of B vitamins in the oral product, for example, about 10% to about 30% by weight, or for example, about 20% to about 30% by weight. In some embodiments, vitamin B12 may be present in an amount of about 0.01% to about 30% by weight of the total amount of B vitamins in the oral product, for example, about 0.01% to about 25% by weight, or for example, about 0.01% to about 15% by weight.
[0055] Taurine, or 2-aminoethanesulfonic acid, is an organic compound widely distributed in animal tissues. Taurine is known to play a role in energy metabolism. The combination of taurine and caffeine can lead to taurine neutralizing some of the negative side effects that excessive caffeine can cause (e.g., tremors or increased heart rate). Including taurine can improve muscle strength and endurance, as well as performance during physical activity. The addition of taurine can also enhance energy metabolism.
[0056] Taurine may be present in any preferred amount, such as at least about 0.001% by weight, at least about 0.01% by weight, or at least about 0.1% by weight of the oral product. In some embodiments, taurine may be present in an amount of about 20% by weight or less, about 10% by weight or less, or about 5% by weight or less of the oral product.
[0057] Taurine may be present in an amount of about 0.001% to about 20% by weight of the oral product. In some embodiments, taurine may be present in an amount of about 0.01% to about 10% by weight of the oral product. Preferably, taurine may be present in an amount of about 0.05% to about 5% by weight of the oral product, or about 0.05% to about 1% by weight of the oral product.
[0058] In some preferred embodiments, taurine is present in an amount of about 0.01% to about 0.1% by weight of the oral product. In other preferred embodiments, taurine is present in an amount of about 0.05% to about 3% by weight of the oral product, for example, about 0.1% to about 2.5% by weight of the oral product, for example, about 0.2% to about 1% by weight of the oral product, for example, about 0.25% to about 0.5% by weight of the oral product.
[0059] In some embodiments, taurine is present in an amount of about 0.1% to about 0.5% by weight of the oral product.
[0060] In addition to caffeine, a combination of B vitamins, and taurine, the combination of active ingredients may include one or more additional active ingredients. These additional active ingredients may be any suitable active ingredients that increase physical and / or mental energy levels and / or increase alertness, and may be selected from, for example, nutritional supplements, nootropics, or psychoactive substances. These additional active ingredients may be naturally occurring or obtained synthetically.
[0061] Non-limiting examples of additional active ingredients include those falling into the categories of plant-derived ingredients (e.g., ginseng, dwarf rhizome, or Rhodiola rosea), stimulants, amino acids or analogues (e.g., L-tyrosine, L-theanine), functional foods, and / or medicinal ingredients (e.g., additional vitamins, e.g., vitamins A, C, D, E, or K, and / or cannabinoids, e.g., tetrahydrocannabinol (THC) and cannabidiol (CBD)).
[0062] Additional active ingredients may include, for example, vitamins such as L-tyrosine, L-theanine, thein, vitamin A, vitamin C, vitamin D, vitamin E, and vitamin K, ginseng, echinacea, cannabinoids, choline, α-GPC, theobromine, guayusa, maca, matcha, methylriverine, nitrates, or beet root juice, yerba mate, glucose, theacrine, or components, derivatives, or combinations thereof.
[0063] In some embodiments, one or more additional active ingredients are selected from plant-derived ingredients (e.g., echinacea, ginseng, peppermint, rosemary, ginger, maca, or herbal tea), stimulants (e.g., guarana), amino acids (e.g., L-theanine, phenylalanine, tyrosine, or tryptophan), cannabinoids, and / or functional foods or medicinal ingredients (e.g., vitamins such as vitamin D, vitamin C, and / or vitamin A).
[0064] In some preferred embodiments, the combination of active ingredients further includes vitamin C (ascorbic acid). Vitamin C acts as an antioxidant, helping to protect cells from damage caused by free radicals. It is also used by the body to produce collagen, a protein that can help heal wounds. Furthermore, vitamin C improves the absorption of iron from plant-based foods and helps the immune system function properly to protect the body from disease.
[0065] The inclusion of vitamin C can reduce lethargy and fatigue, and improve energy metabolism.
[0066] If present, vitamin C may be present in any preferred amount, such as at least about 0.001% by weight, at least about 0.01% by weight, or at least about 0.1% by weight of the oral product. In some embodiments, vitamin C may be present in an amount of about 20% by weight or less, about 10% by weight or less, or about 5% by weight or less of the oral product.
[0067] If present, vitamin C may be present in an amount of about 0.01% to about 20% by weight, or about 0.05% to about 10% by weight, of the oral product. Preferably, vitamin C may be present in an amount of about 0.1% to about 5% by weight, of the oral product. In some embodiments, vitamin C is present in an amount of about 0.2% to about 2.5% by weight, and preferably about 0.5% to about 1% by weight, of the oral product.
[0068] In some embodiments, the combination of active ingredients further includes ginseng. Ginseng is the root of plants of the genus Panax and is characterized by the presence of unique steroid saponin phytochemicals (ginsenosides) and gintonin. The presumed major active ingredients of ginseng include more than 100 specific triterpene saponins or "ginsenosides." Ginseng and ginseng extracts also contain a range of other potentially bioactive components, including alkaloids, phytosterols, sesquiterpenes, and polyphenols. Ginseng has been found to be used in nutritional drinks or herbal teas and as a dietary supplement in traditional medicine.
[0069] Ginseng may include any preferred form of ginseng, such as Panax ginseng (Korean ginseng), Panax ginseng (Chinese ginseng), and American ginseng (US ginseng). Ginseng may also include Ashwagandha (Withania somnifera), commonly known as Indian ginseng. Ginseng may exist in the form of ginseng extract, coarsely chopped ginseng, finely chopped ginseng, or powdered ginseng. Preferably, ginseng is included in the form of ginseng extract or powdered ginseng extract. Ginseng may be white ginseng, fresh ginseng, or red ginseng. In some embodiments, ginseng is red ginseng, such as red ginseng extract or powdered red ginseng extract. The addition of ginseng has been found to enhance brain function and / or increase cognitive effects. The inclusion of ginseng has been found to be beneficial in improving the cognitive effects of the composition and reducing mental and physical fatigue in the user.
[0070] If present, ginseng may be included in any preferred amount, such as at least about 0.0001% by weight, at least about 0.001% by weight, or at least about 0.01% by weight of the oral product. In some embodiments, ginseng is present in an amount of about 0.0001% to about 5% by weight of the oral product. In some embodiments, ginseng is present in an amount of about 0.001% to about 1% by weight of the oral product. In some embodiments, ginseng is present in an amount of about 0.001% to about 0.1% by weight of the oral product. In some embodiments, ginseng is present in an amount of about 0.01% to about 0.05% by weight of the oral product. Ginseng may be present in an amount of about 2% by weight or less of the oral product, for example, about 1% by weight or less.
[0071] In some preferred embodiments, the combination of active ingredients further comprises ginseng in an amount of about 0.001% to about 1% by weight of the oral product, preferably about 0.01% to about 0.1% by weight of the oral product.
[0072] In some preferred embodiments, the combination of active ingredients includes caffeine, a combination of B vitamins, taurine, and ginseng.
[0073] In some preferred embodiments, the combination of active ingredients includes caffeine, a combination of B vitamins, taurine, and vitamin C.
[0074] In some preferred embodiments, the combination of active ingredients includes caffeine, a combination of B vitamins, taurine, vitamin C, and ginseng.
[0075] In some embodiments, the combination of active ingredients includes (i) caffeine in an oral product of about 0.01% to about 10% by weight, (ii) a combination of B vitamins in a total amount of about 0.001% to about 5% by weight of the oral product, and (iii) taurine in an oral product of about 0.001% to about 10% by weight. In some embodiments, the combination of active ingredients includes (i) caffeine in an oral product of about 0.1% to about 5% by weight, (ii) a combination of B vitamins in a total amount of about 0.001% to about 1% by weight of the oral product, and (iii) taurine in an oral product of about 0.01% to about 5% by weight. In some embodiments, the combination of active ingredients includes (i) caffeine in an oral product of about 0.1% to about 1% by weight, (ii) a combination of B vitamins in a total amount of about 0.01% to about 1% by weight of the oral product, and (iii) taurine in an oral product of about 0.1% to about 1% by weight.
[0076] In some embodiments, the combination of active ingredients includes (i) caffeine in an oral product of about 0.1% to about 1% by weight, (ii) a combination of B vitamins in a total amount of about 0.01% to about 1% by weight of the oral product, and (iii) taurine in an oral product of about 0.01% to about 0.5% by weight.
[0077] In any of these embodiments, the combination of active ingredients may further contain vitamin C in an amount of about 0.1% to about 5% by weight of the oral product. In any of these embodiments, the combination of active ingredients may further contain ginseng in an amount of about 0.001% to about 1% by weight of the oral product, or about 0.01% to about 0.1% by weight of the oral product. In any of these embodiments, the combination of active ingredients may further contain vitamin C in an amount of about 0.1% to about 5% by weight of the oral product, and ginseng in an amount of about 0.01% to about 1% by weight of the oral product.
[0078] In some embodiments, the combination of active ingredients includes (i) caffeine in an oral product of about 0.01% to about 10% by weight, (ii) a combination of B vitamins in a total amount of about 0.001% to about 5% by weight, (iii) taurine in an oral product of about 0.001% to about 10% by weight, and (iv) vitamin C in an oral product of about 0.05% to about 10% by weight. In some embodiments, the combination of active ingredients includes (i) caffeine in an oral product of about 0.1% to about 5% by weight, (ii) a combination of B vitamins in a total amount of about 0.001% to about 1% by weight, (iii) taurine in an oral product of about 0.01% to about 5% by weight, and (iv) vitamin C in an oral product of about 0.1% to about 5% by weight. In some embodiments, the combination of active ingredients includes (i) caffeine in an oral product of about 0.1% to about 1% by weight, (ii) a combination of B vitamins in a total amount of about 0.01% to about 1% by weight of the oral product, (iii) taurine in an oral product of about 0.01% to about 1% by weight, and (iv) vitamin C in an oral product of about 0.1% to about 1% by weight.
[0079] In some embodiments, the combination of active ingredients includes (i) caffeine in an oral product of about 0.01% to about 5% by weight, (ii) a combination of B vitamins in a total amount of about 0.001% to about 1% by weight of the oral product, (iii) taurine in an oral product of about 0.01% to about 5% by weight, and (iv) vitamin C in an oral product of about 0.1% to about 5% by weight.
[0080] In some embodiments, the combination of active ingredients includes (i) caffeine in an oral product of about 0.1% to about 5% by weight, (ii) a combination of B vitamins in a total amount of about 0.001% to about 1% by weight of the oral product, (iii) taurine in an oral product of about 0.01% to about 5% by weight, and (v) ginseng in an oral product of about 0.01% to about 1% by weight.
[0081] In some embodiments, the combination of active ingredients includes (i) caffeine in an oral product of about 0.1% to about 5% by weight, (ii) a combination of B vitamins in a total amount of about 0.001% to about 1% by weight of the oral product, (iii) taurine in an oral product of about 0.01% to about 5% by weight, (iv) vitamin C in an oral product of about 0.1% to about 5% by weight, and (v) ginseng in an oral product of about 0.01% to about 1% by weight.
[0082] The inventors have found that the amounts of the active ingredients described above provide beneficial effects such as increasing energy levels and enhancing brain function, while also providing a safe product with reduced side effects. The amounts can be adjusted to ensure high efficacy while guaranteeing consumer safety and avoiding any excessive intake of the active ingredients.
[0083] Other suitable additional active ingredients are listed below.
[0084] L-theanine is L-γ-glutamylethylamide and N 5 It is an amino acid analog also called ethyl-L-glutamine. If present, L-theanine may be present in an amount of about 0.01% to about 10% by weight of the oral product. Preferably, L-theanine may be present in an amount of about 0.1% to about 5% by weight of the oral product.
[0085] In some embodiments, the combination of active ingredients further includes botanical active ingredients. As used herein, the terms “botanical ingredient” or “botanical” refer to any plant material or fungal material, including plant materials in their natural forms and plant materials derived from natural plant materials, e.g., extracts or isolates from plant materials or processed plant materials (e.g., plant materials subjected to heat treatment, fermentation, bleaching, or other processing processes that can alter the physical and / or chemical properties of the material). For the purposes of this disclosure, “botanical” includes, but is not limited to, “herbal materials,” which refer to seed-producing plants that do not develop persistent woody tissue and are often valued for their medicinal or sensory properties (e.g., tea or herbal tea). Botanical materials useful in this disclosure may include, but is not limited to, any compounds and sources (including mixtures thereof) described herein. Certain botanical materials of this type may be called dietary supplements, nutritional supplements, “phytochemicals” or “functional foods.” Certain botanical substances as plant materials or extracts thereof have been found to have use in traditional herbal medicines, which are further described herein.Non-exclusive examples of plant-based or plant-derived materials include ashwagandha, Otome-azena, baobab, basil, centella asiatica, bupleurum, chamomile, cherry blossoms, chlorophyll, cinnamon, citrus fruits, cloves, cocoa, cordyceps, curcumin, damiana, dorstenia alifolia, dorstenia odorata, essential oils, eucalyptus, fennel, Galphimia glauca, ginger, ginkgo, ginseng (e.g., Panax ginseng), Griffonia simplicifolia, guarana, cannabis, hemp, hops, jasmine, black ginger (Thai ginseng), and kaba. Examples include lavender, lemon balm, lemongrass, lycoris, lutein, maca, matcha, Nardo statischinensis, sweet violet oil extract, peppermint, quercetin, resveratrol, Gastrodia elata, passionflower, guayusa, maca, matcha, beetroot juice, Rhodiola rosea, rooibos, rose essential oil, rosemary, Selenium tortuosum, Schisandra chinensis, skullcap, spearmint extract, spikenard, terpenes, herbal tea, turmeric, Turnera aphrodisi, valerian, mulberry, echinacea, and yerba mate.
[0086] In some embodiments, the combination of active ingredients further includes echinacea, a genus of herbaceous flowering plants of the family Asteraceae, commonly known as cornflower. If present, echinacea may be present in an amount of about 0.001% to about 3% by weight of the oral product, and preferably about 0.01% to about 1% by weight of the oral product.
[0087] The combination of active ingredients may further include vitamins selected from vitamin A, vitamin D, vitamin E, and vitamin K, or mixtures thereof. In some preferred embodiments, the combination of active ingredients may further include vitamin D in an amount of about 0.001% to about 1% by weight of the oral product.
[0088] The combination of active ingredients may further include amino acids, such as amino acids selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, gamma-aminobutyric acid (GABA), L-theanine, hydroxyproline, and β-alanine. In some embodiments, the combination of active ingredients includes L-tyrosine.
[0089] In some embodiments, the combination of active ingredients includes one or more of the following: choline, αGPC, theobromine, guayusa, maca, matcha, methylriverine, nitrate or beet root juice, yerba mate, glucose, or theacrin.
[0090] In some embodiments, the active ingredient combination includes cannabinoids. Cannabinoids may be derivatives or extracts of cannabis. Cannabinoids are a class of naturally occurring or synthetic chemical compounds that act on intracellular cannabinoid receptors (i.e., CB1 and CB2) that inhibit the release of neurotransmitters in the brain. Cannabinoids are cyclic molecules that exhibit certain properties, such as the ability to easily cross the blood-brain barrier. Cannabinoids may be naturally occurring from plants such as cannabis (phytocannabinoids), from animals (endocannabinoids), or artificially produced (synthetic cannabinoids). Cannabis species represent at least 85 different phytocannabinoids, which can be classified into subclasses including cannabigerol, cannabichromene, cannabidiol, tetrahydrocannabinol, cannabinol, cannabinodiol, and other cannabinoids. In some embodiments, the cannabinoid is selected from the group consisting of cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol (CBN), and cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabiclomevalin (CBCV), cannabigerovalin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerol acid, cannabidiolic acid (CBDA), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabimolic acid (THCA), tetrahydrocannabivaric acid (THCV A), and mixtures thereof. In some embodiments, the cannabinoid is tetrahydrocannabinol (THC) or comprises at least tetrahydrocannabinol (THC). In some embodiments, the cannabinoid is cannabidiol (CBD) or comprises at least cannabidiol (CBD).
[0091] In some embodiments, the active ingredient combination contains at least about 0.001% by weight of cannabinoids (such as cannabidiol) in an amount ranging from about 0.001% to about 10% by weight, for example, about 0.01% to about 5% by weight, for example, about 0.1% to about 2.5% by weight, for example, 0.5% to about 1% by weight of the oral product.
[0092] In some embodiments, the combination of active ingredients includes magnesium glycinate. If present, magnesium glycinate may be included in the oral product in an amount of about 0.1% to about 10% by weight, for example, about 0.5% to about 5% by weight, or about 0.5% to about 1% by weight.
[0093] To avoid misunderstanding, the above combinations of endpoints are expressly assumed by this disclosure. This applies to any scope disclosed herein.
[0094] Ratio of active ingredients The ratio of active ingredients in an oral product may be selected to increase the cognitive effect of the oral product on consumers.
[0095] In some embodiments, caffeine and taurine are present in a weight ratio of about 10:1 to about 1:10, preferably about 5:1 to about 1:5, and more preferably about 5:1 to about 1:1. In preferred embodiments, caffeine and taurine may be present in a weight ratio of about 3:1. Alternatively, caffeine and taurine may be present in a weight ratio of about 2:1 to about 4:1.
[0096] In some embodiments, the total amounts of caffeine and B vitamins are present in a weight ratio of about 1:1 to about 15:1, for example, about 1:1 to about 10:1. In preferred embodiments, the total amounts of caffeine and B vitamins are present in a weight ratio of about 2:1 to about 10:1, or 3:1 to about 5:1. In particularly preferred embodiments, the total amounts of caffeine and B vitamins are present in a weight ratio of about 2:1 to about 10:1.
[0097] In some embodiments, the total amounts of taurine and B vitamins are present in a weight ratio of about 10:1 to about 1:2, for example, about 7.5:1 to about 1:2. In some preferred embodiments, the total amounts of taurine and B vitamins are present in a weight ratio of about 7.5:1 to about 2:1. In other preferred embodiments, the total amounts of taurine and B vitamins are present in a weight ratio of about 1:1 to about 1:2. In preferred embodiments, the total amounts of taurine and B vitamins are present in a weight ratio of about 5:1 to about 1:2, or 3:1 to about 1:2.
[0098] If present, the proportion of ginseng in the product may also provide benefits for improving cognitive function and mental attention. If present, ginseng may be present in amounts such that the weight ratio of caffeine to ginseng is about 50:1 to about 1:1, for example, about 45:1 to about 15:1. Preferably, ginseng may be present in amounts such that the weight ratio of caffeine to ginseng is about 40:1 to about 30:1. Alternatively, if present, ginseng may be present in amounts such that the weight ratio of caffeine to ginseng is about 60:1 to about 1:1, for example, about 60:1 to about 15:1. Preferably, ginseng may be present in amounts such that the weight ratio of caffeine to ginseng is about 60:1 to about 20:1.
[0099] If present, ginseng may be present in amounts such that the weight ratio of taurine to ginseng is about 5:1 to about 50:1. In some embodiments, the weight ratio of taurine to ginseng is about 5:1 to about 40:1, for example, about 10:1 to about 30:1. In some embodiments, the weight ratio of taurine to ginseng is about 10:1 to about 20:1.
[0100] In some embodiments (for example, when the oral product is in the form of a lozenge or chew), taurine and ginseng are present in a weight ratio of about 5:1 to about 50:1, for example, about 10:1 to about 20:1. In some embodiments (for example, when the oral product is in the form of a lozenge or chew), taurine and ginseng are present in a weight ratio of about 10:1 to about 30:1. In some embodiments (for example, when the oral product is in the form of a lozenge or chew), caffeine and ginseng are present in a weight ratio of about 10:1 to about 100:1, for example, about 20:1 to about 50:1. In some embodiments (for example, when the oral product is in the form of a lozenge or chew), caffeine and ginseng are present in a weight ratio of about 30:1 to about 60:1.
[0101] If present, vitamin C may be included such that the weight ratio of vitamin C to caffeine is about 5:1 to about 1:5. In some preferred embodiments, the weight ratio of vitamin C to caffeine is about 3:1 to about 1:3, more preferably about 2:1 to about 1:1 or about 3:1 to about 1:2. If present, vitamin C may be included such that the weight ratio of vitamin C to taurine is about 15:1 to about 1:5. In some preferred embodiments, the weight ratio of vitamin C to taurine is about 10:1 to about 1:1, more preferably about 10:1 to about 2:1. If present, vitamin C may be included such that the weight ratio of vitamin C to total B vitamins is about 1:1 to about 15:1.
[0102] In some embodiments, the oral product is (i) caffeine, (ii) a combination of B vitamins, and (iii) taurine are included in the combination of active ingredients. Here, the weight ratio of caffeine to taurine is approximately 5:1 to approximately 1:1. The weight ratio of caffeine to the total amount of B vitamins is approximately 1:1 to 10:1. The weight ratio of taurine to the total amount of B vitamins is approximately 10:1 to 1:2.
[0103] In some embodiments, the oral product is (i) caffeine, (ii) a combination of B vitamins, and (iii) taurine are included in the combination of active ingredients. Here, the weight ratio of caffeine to taurine is approximately 3:1, and the combination of B vitamins is as described in any of the embodiments above.
[0104] In some embodiments, the oral product is (i) caffeine, (ii) a combination of B vitamins, and (iii) taurine are included in the combination of active ingredients. Here, the weight ratio of caffeine to taurine is approximately 2:1 to 4:1, and the combination of B vitamins is as described in any of the embodiments above.
[0105] In some embodiments, the oral product is (i) caffeine, (ii) a combination of B vitamins, (iii) taurine, and (iv) ginseng are included in the combination of active ingredients. Here, the weight ratio of caffeine to ginseng is approximately 40:1 to 130:1, and in some cases, the weight ratio of caffeine to taurine is approximately 4:1 to 1:1.
[0106] In some embodiments, the oral product is (i) caffeine, (ii) a combination of B vitamins, (iii) taurine, and (iv) ginseng are included in the combination of active ingredients. Here, the weight ratio of caffeine to taurine is approximately 4:1 to approximately 1:1. The weight ratio of caffeine to the total amount of B vitamins is approximately 1:1 to approximately 10:1, and The weight ratio of caffeine to ginseng is approximately 240:1 to 30:1.
[0107] additives Depending on the type of oral product being processed, the product may contain one or more additional ingredients in addition to the combination of active ingredients. For example, an oral product may further contain additives selected from the group consisting of flavoring agents, sweeteners, buffers, acidifiers, thickeners, fillers, binders, humectants, preservatives, salts, colorants, oral care additives, disintegrants, antioxidants, water, or mixtures thereof. In some embodiments, the oral product further contains one or more additives selected from the group consisting of flavoring agents, sweeteners, acidifiers, thickeners, fillers, binders, humectants, preservatives, and mixtures thereof.
[0108] Filler or bulking agent Depending on the product form, oral products may contain fillers or bulking agents. Fillers or bulking agents can perform multiple functions, such as improving certain sensory characteristics like texture and mouthfeel, or improving the cohesiveness or compressibility of the product.
[0109] In some embodiments, the filler is a porous granular material and is cellulosic. For example, the filler or bulking agent may be a non-tobacco plant material or a derivative thereof, and includes cellulosic materials derived from such sources. Examples of cellulosic non-tobacco plant materials include cereals (e.g., corn, oats, barley, rye, buckwheat, etc.), sugar beets (e.g., FIBREX® brand fillers available from International Fiber Corporation), bran fibers, and mixtures thereof. In some embodiments, the filler is a cellulosic material selected from the group consisting of corn fiber, oat fiber, barley fiber, rye fiber, buckwheat fiber, sugar beet fiber, bran fiber, bamboo fiber, wood pulp fiber, cotton fiber, citrus pulp fiber, plant fiber, willow fiber, poplar fiber, cocoa fiber, derivatives thereof, and combinations thereof. In some embodiments, the filler is a cellulosic material selected from the group consisting of sugar beet fiber, wood pulp fiber, bamboo fiber, derivatives thereof, and combinations thereof.
[0110] In some embodiments, the filler is derived from wood pulp fibers. One filler particularly suitable for use in the products described herein is microcrystalline cellulose ("MCC"). MCC may be synthetic, semi-synthetic, or obtained entirely from natural cellulose. MCC may be selected from the group consisting of AVICEL® grades PH-100, PH-101, PH-102, PH-103, PH-105, PH-112, PH-113, PH-200, PH-300, PH-301, PH-302, VIVACEL® grades 101, 102, 12, 20, and EMOCEL® grades 50M and 90M, as well as mixtures thereof.
[0111] In some embodiments, the filler is a non-tobacco plant material or a derivative thereof. Non-limiting examples of derivatives of non-tobacco plant materials include starch (e.g., potato, wheat, rice, corn), natural cellulose, and modified cellulose materials. Further examples of potential fillers include maltodextrin, dextrose, calcium carbonate, calcium phosphate, lactose, mannitol, xylitol, and sorbitol. Combinations of these fillers can also be used.
[0112] As used herein, “starch” may refer to pure starch, modified starch, or starch derivatives from any source. Starch is typically present in granular form in almost all green plants and various types of plant tissues and organs (e.g., seeds, leaves, rhizomes, roots, tubers, sprouts, fruits, grains, and stems). Starch can vary in composition, as well as in the shape and size of its granules. Often, starches from different sources have different chemical and physical characteristics. Specific starches can be selected for inclusion in a product based on their ability to impart specific sensory properties to the product. Starches from a variety of sources can be used. For example, major sources of starch include cereals (e.g., rice, wheat, and corn) and root vegetables (e.g., potatoes and cassava). Other examples of starch sources include acorns, arrowroot, arakacha, bananas, barley, legumes (e.g., broad beans, lentils, mung beans, peas, chickpeas), breadfruit, buckwheat, canna, chestnut, taro, dogtooth violet, kudzu, maranga, millet, oats, wood sorrel, taro, sago, sorghum, sweet potato, quinoa, rye, tapioca, taro, tobacco, water chestnut, and yam. Certain starches are modified starches. Modified starches undergo one or more structural modifications, often designed to alter their high thermal properties. Some starches are developed through genetic modification and are considered "modified" starches. Other starches are obtained and subsequently processed. For example, modified starch may be starch subjected to chemical reactions such as esterification, etherification, oxidation, depolymerization (dilution) by oxidation in the presence of an acid catalyst or a base, bleaching, glycosylation and depolymerization (e.g., dextrinization in the presence of a catalyst), crosslinking, enzymatic treatment, acetylation, hydroxypropylation, and / or partial hydrolysis. Other starches are processed by heat treatments such as gelatinization, dextrinization, and / or cold water swelling processes.Specific modified starches include phosphorylated starch, glycerol cross-linked starch, phosphate cross-linked starch esterified with sodium trimetaphosphate, phosphorylated phosphate cross-linked starch, acetylated phosphate cross-linked starch, acetate starch esterified with acetic anhydride, acetate starch esterified with vinyl acetate, acetylated adipic acid cross-linked starch, acetylated glycerol cross-linked starch, hydroxypropyl starch, hydroxypropyl glycerol cross-linked starch, and sodium octenyl succinate starch.
[0113] Other suitable fillers or fillers include sugar alcohols. Sugar alcohols are polyols derived from monosaccharides or disaccharides in partially or fully hydrogenated forms. Sugar alcohols include, for example, those having about 4 to about 20 carbon atoms, such as erythritol, arabitol, ribitol, isomalt, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, sorbitol, and combinations thereof. In some embodiments, if present, the filler may be selected from the group consisting of isomalt, maltitol, and mixtures thereof.
[0114] water The water content (e.g., water content) of oral products may change according to the desired characteristics before the product is used by the consumer.
[0115] Typically, for solid oral products, the water content before insertion into the user's mouth is less than about 60% by weight of the oral product, generally ranging from about 1% to about 60% by weight, for example, about 5% to about 55% by weight, about 10% to about 50% by weight, about 20% to about 45% by weight, or about 25% to about 40% by weight, and includes at least about 5% by weight, at least about 10% by weight, at least about 15% by weight, and at least about 20% by weight of water in the oral product.
[0116] Flavoring As used herein, the terms “flavoring agent” (or “flavor” and “flavoring agent”) refer to materials that may be used to create a desired taste, aroma, or other somatic sensation in a product intended for adult consumers, where local regulations permit it. Examples of sensory characteristics that may be modified by flavoring agents include taste, texture, moisture, coolness / heat, and / or aroma / fragrance. Flavoring agents may be natural or synthetic, and the flavor characteristics they impart may be described as, but are not limited to, fresh, sweet, herbal, confectionery, floral, fruity, or spicy.
[0117] Flavorings include naturally occurring flavorings, plant substances, extracts of plant substances, synthetically obtained materials, or combinations thereof (e.g., tobacco, cannabis, licorice, hydrangea, eugenol, magnolia leaves, chamomile, fenugreek, clove, maple, matcha, menthol, Japanese mint, anise, cinnamon, turmeric, Indian spices, Asian spices, herbs, wintergreen, cherry, berries, red berries, cranberries, peaches, apples, oranges, mangoes, clementines, lemons, limes, tropical fruits). Caramel fruit, papaya, rhubarb, grapes, durian, dragon fruit, cucumber, blueberry, mulberry, citrus fruits, Drambuie, bourbon, scotch, whiskey, gin, tequila, rum, spearmint, peppermint, lavender, aloe vera, cardamom, coconut, celery, cascarilla, nutmeg, sandalwood, bergamot, geranium, kurt, eggplant, betel nut, shisha, pine, honey essence, rose oil, vanilla, lemon oil, orange oil, orange blossom, cherry blossom, cassia, caraway, cognac, jasmine, ylang-yi Orchid, sage, fennel, wasabi, bell pepper, ginger, coriander, coffee, hemp, peppermint oil from any of the Mentha species, eucalyptus, star anise, cocoa, lemongrass, rooibos, flax, ginkgo, hazelnut, hibiscus, bay leaf, mate, orange peel, rose, tea such as green or black tea, thyme, juniper, elderflower, basil, bay leaf, cumin, oregano, paprika, rosemary, saffron, lemon peel, mint, shiso, curcuma, cilantro, myrtle, blackcurrant, valerian, pimento, mace, damien, marjoram, The additives may be selected from the group consisting of olives, lemon balm, lemon basil, chives, calvi, verbena, tarragon, limonene, thymol, camphene), flavor enhancers, bitter taste receptor site blockers, sensory receptor site activators or stimulants, sugars and / or sugar substitutes (e.g., honey, sucralose, acesulfame potassium, aspartame, saccharin, cyclamate, lactose, sucrose, glucose, fructose, sorbitol, or mannitol), and other additives such as charcoal, chlorophyll, minerals, plant-based substances, or breath fresheners.Flavoring agents may be imitation, synthetic, or natural ingredients, or blends thereof. Flavoring agents may be in any suitable form, such as a liquid such as an oil, a solid such as a powder, or a gas.
[0118] In some embodiments, the flavoring agents include natural flavoring agents such as berries (e.g., raspberries, blueberries, or strawberries), honey, citrus fruits (such as lemons, bergamots, oranges, or limes), or other plant-based materials.
[0119] In some embodiments, the flavoring agent includes menthol, spearmint, and / or peppermint. In some embodiments, the flavoring agent includes flavor components of cucumber, blueberry, citrus, and / or red berry. In some embodiments, the flavoring agent includes eugenol. In some embodiments, the flavoring agent includes flavor components extracted from tobacco. In some embodiments, the flavoring agent includes flavor components extracted from cannabis.
[0120] In some embodiments, the flavoring agent may include a sensory stimulant, which is intended to achieve somatosensations that are normally chemically induced and perceived by stimulation of the fifth cranial nerve (trigeminal nerve) in addition to, or instead of, the aroma or taste nerves, and these may include agents that produce heating, cooling, tingling, or numbing effects. A preferred thermal agent may be, but is not limited to, vanillyl ethyl ether, and a preferred cooling agent may be, but is not limited to, eucalyptol or WS-3.
[0121] If present, flavoring agents may be included in the oral product in an amount of up to about 10% by weight of the oral product, for example, up to about 5% by weight, for example, up to about 1% by weight. In some embodiments, flavoring agents are present in an amount of about 0.01% to about 5% by weight of the oral product, preferably about 0.1% to about 2.5% by weight, and more preferably about 0.25% to about 1% by weight of the oral product.
[0122] Binder In some embodiments, the oral product may further contain at least one binder. In certain embodiments, the binder (or combination of binders) may be used in the product in an amount sufficient to provide the product with the desired physical attributes and physical integrity.
[0123] The binder may be organic, inorganic, or a combination thereof. Typical binders include cellulose derivatives, povidone, sodium alginate, starch-based binders, pectin, carrageenan, pullulan, zein, and combinations thereof. The amount of binder used in the product may vary, but may be up to about 30% by weight, and specific embodiments are characterized by a binder content of at least about 0.1% by weight, for example, about 1% to about 30% by weight, or about 1% to about 10% by weight, based on the total weight of the oral product.
[0124] In some embodiments, the binder includes pectin. Pectin is a natural polymer related to carbohydrates and is an acidic heteropolysaccharide (a polysaccharide containing multiple monosaccharide units). In contrast to carbohydrates, the C-6 position of pectin contains a carboxylic acid (or the corresponding methyl ester or carboxamide) group instead of a hydroxymethyl group. The major subunit is known as galacturonic acid and can be copolymerized with L-rhamnose. Other sugars are characterized as side-chain substituents. Pectin acts as a thickening agent and gelling agent. Pectin isolated from sources, e.g., apple juice residue, citrus peel, sugar beet waste from sugar production, sunflower heads discarded from seed harvesting, mango waste, and other commercially available pectin may be used. In combination with certain sugars, under acidic conditions (e.g., pH about 2.5 to about 5) or in the presence of a gelling agent (calcium or other divalent alkaline earth elements), pectin can provide the consistency of a gel or gum to the products disclosed herein. In some embodiments, the binder comprises low methoxypectin. A suitable low methoxypectin includes, for example, "GENU® Pectin Type LM-104 AS," available from CP Kelco (Atlanta, Georgia, USA). In some embodiments, the binder comprises low methoxypectin in combination with a gelling agent. In some embodiments, the gelling agent comprises calcium ions, for example, calcium diphosphate, but is not limited. In some embodiments, the binder comprises high methoxypectin in combination with an organic acid described below herein. In some embodiments, the binder comprises high methoxypectin in combination with citric acid.
[0125] If present, the pectin binder is typically present in amounts up to about 3% by weight, based on the total weight of the oral product, for example, from about 0.1% by weight, about 0.2% by weight, about 0.3% by weight, about 0.4% by weight, about 0.5% by weight, about 0.6% by weight, about 0.7% by weight, about 0.8% by weight, about 0.9% by weight, or about 1% by weight, to about 1.1% by weight, about 1.2% by weight, about 1.3% by weight, about 1.4% by weight, about 1.5% by weight, about 1.6% by weight, about 1.7% by weight, about 1.8% by weight, about 1.9% by weight, about 2% by weight, about 2.1% by weight, about 2.2% by weight, about 2.3% by weight, about 2.4% by weight, about 2.5% by weight, about 2.6% by weight, about 2.7% by weight, about 2.8% by weight, about 2.9% by weight, or about 3% by weight.
[0126] In some embodiments, the binder includes a cellulose derivative. In certain embodiments, the cellulose derivative is a cellulose ether (including carboxyalkyl ethers), meaning a cellulose polymer in which one or more hydrogens of hydroxyl groups in the cellulose structure are replaced by alkyl, hydroxyalkyl, or aryl groups. Non-limiting examples of such cellulose derivatives include methylcellulose, hydroxypropylcellulose ("HPC"), hydroxypropylmethylcellulose ("HPMC"), hydroxyethylcellulose, and carboxymethylcellulose ("CMC"). In some embodiments, the cellulose derivative is HPC or includes HPC. In some embodiments, the cellulose derivative is a combination of HPC and HPMC. In some embodiments, the oral product contains about 1% to about 10% by weight of the cellulose derivative (such as HPC) of the oral product, and in certain embodiments, it contains about 1% to about 5% by weight of the cellulose derivative (such as HPC), based on the weight of the product.
[0127] In certain embodiments, the binder includes gum, such as natural gum. As used herein, natural gum refers to naturally occurring polysaccharide materials that have binding properties and are also useful as thickeners or gelling agents. Typical natural gums of plant origin that are somewhat water-soluble include xanthan gum, guar gum, gum arabic, ghati gum, tragacanth gum, karaya gum, locust bean gum, gellan gum, and combinations thereof. Where present, the natural gum binder material may be present in amounts from up to about 5% by weight, for example, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, or about 1%, based on the total weight of the product, to about 2%, about 3%, about 4%, or about 5% by weight.
[0128] Humectant In some embodiments, the oral product contains at least one wetting agent. Examples of suitable wetting agents that may be included in the product include, but are not limited to, glycerin, 1,2-propanediol (propylene glycol), 1,3-propanediol, dipropylene glycol, sorbitol, xylitol, and mannitol. In some embodiments, the wetting agent is glycerin or contains glycerin. In some embodiments, the oral product contains glycerin. In some embodiments, the wetting agent is propylene glycol or contains propylene glycol. In some embodiments, the oral product contains polypropylene glycol. The amount of wetting agent used in the oral product can vary, but may be up to about 5% by weight, and certain embodiments are characterized by a wetting agent content of at least about 1% by weight, for example, about 2% to about 5% by weight, in the oral product. In some embodiments, a wetting agent (such as glycerin and / or propylene glycol) may be present in an amount of about 0.01% to about 25% by weight of the oral product, for example, about 0.1% to about 20% by weight of the oral product, for example, about 0.5% to about 15% by weight of the oral product, for example, about 1% to about 10% by weight of the oral product, for example, about 5% to about 10% by weight of the oral product.
[0129] sweetener To improve the sensory characteristics of an oral product, one or more sweeteners may be added. The sweeteners can be any sweetener or combination of sweeteners, either in natural or artificial form, or as a combination of natural and artificial sweeteners. Examples of natural sweeteners include fructose, sucrose, glucose, maltose, mannose, galactose, lactose, stevia, and honey. Examples of artificial sweeteners include sucralose, isomaltulose, maltodextrin, saccharin, aspartame, acesulfame K, and neotame.
[0130] In some embodiments, the sweetener comprises one or more sugar alcohols. Examples of sugar alcohols include erythritol, arabitol, ribitol, isomalt, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, sorbitol, and combinations thereof. In some embodiments, the sweetener is selected from the group consisting of fructose, sucrose, glucose, maltose, mannose, galactose, lactose, stevia, honey, sucralose, isomaltulose, maltodextrin, saccharin, aspartame, acesulfame K, neotame, erythritol, arabitol, ribitol, isomalt, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, sorbitol, and mixtures thereof.
[0131] In some embodiments, the sweetener is selected from the group consisting of sucralose, acesulfame K, aspartame, maltodextrin, mannitol, sucrose, and mixtures thereof. Preferably, the sweetener may be sucralose and / or acesulfame K. When present in the oral product, the sweetener (such as sucralose and / or acesulfame K) may be present in an amount of about 0.001% to about 5% by weight, for example, about 0.01% to about 3% by weight, preferably about 0.01% to about 1% by weight, of the oral product.
[0132] cushioning agent Non-limiting examples of suitable buffers that may be included in the oral product include alkali metal acetates, glycinates, phosphates, glycerophosphates, citrates, carbonates, bicarbonates, borates, or mixtures thereof. In some embodiments where a buffer is present, the buffer is selected from the group consisting of sodium carbonate, sodium bicarbonate, sodium phosphate, ammonium phosphate, dicalcium phosphate, tricalcium phosphate, and mixtures thereof. In some embodiments, the buffer is sodium bicarbonate and / or sodium carbonate. If present, the buffer (e.g., sodium bicarbonate and / or sodium carbonate) may be included in amounts less than about 5% by weight of the oral product, for example, about 0.5% to about 5% by weight based on the total weight of the oral product, for example, about 0.75% to about 4% by weight, about 0.75% to about 3% by weight, or about 1% to about 2% by weight.
[0133] organic acid In some embodiments, the product contains organic acids. As used herein, the term “organic acid” refers to an organic (i.e., carbon-based) compound characterized by its acidic properties. Typically, organic acids are relatively weak acids (i.e., they do not completely dissociate in the presence of water), such as carboxylic acids (-CO2H) or sulfonic acids (-SO2OH). As used herein, references to organic acids mean organic acids that are intentionally added. In this regard, organic acids may be intentionally added as specific mixture components rather than simply existing as components of another mixture component (e.g., small amounts of organic acids that may be essentially present in a mixture such as tobacco material). In some embodiments, one or more organic acids are added as is (i.e., in their free acid, natural solid or liquid form) or as a solution in water, for example. In some embodiments, one or more organic acids are added in the form of salts.
[0134] In some embodiments, the organic acid is a carboxylic acid or sulfonic acid. The carboxylic acid or sulfonic acid functional group is, for example, 1 to 20 carbon atoms (C1 to C2). 20It may be bonded to any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group having ). In some embodiments, the organic acid is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroarylcarboxylic acid or sulfonic acid.
[0135] In some embodiments, the organic acid is an alkylcarboxylic acid. Non-limiting examples of alkylcarboxylic acids include formic acid, acetic acid, propionic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, stearic acid, oleic acid, linoleic acid, and linolenic acid. In some embodiments, the organic acid is an alkylsulfonic acid. Non-limiting examples of alkylsulfonic acids include propanesulfonic acid and octanesulfonic acid.
[0136] In some embodiments, the alkylcarboxylic acid or sulfonic acid is substituted with one or more hydroxyl groups. Non-limiting examples include glycolic acid, 4-hydroxybutyric acid, and lactic acid.
[0137] In some embodiments, the organic acid may contain two or more carboxylic acid groups or two or more sulfonic acid groups (e.g., two, three, or more carboxylic acid groups). Non-limiting examples include oxalic acid, fumaric acid, maleic acid, and glutaric acid. In organic acids containing multiple carboxylic acids (e.g., two to four carboxylic acid groups), one or more carboxylic acid groups may be esterified. Non-limiting examples include monoethyl succinate, monomethyl fumarate, monomethyl citrate, or dimethyl citrate.
[0138] In some embodiments, the organic acid may comprise two or more carboxylic acid groups and one or more hydroxyl groups. Non-limiting examples of such acids include tartaric acid and citric acid. In some preferred embodiments, the organic acid is citric acid, sodium citrate, calcium citrate, or a combination thereof.
[0139] In some embodiments, the organic acid is an arylcarboxylic acid or an arylsulfonic acid. Non-limiting examples of arylcarboxylic acids and sulfonic acids include benzoic acid, tolueneic acid, salicylic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
[0140] Further non-limiting examples of suitable organic acids include 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid (L), aspartic acid (L), camphoric acid (+), camphor-10-sulfonic acid (+), capric acid, caproic acid, caprylic acid, cinnamic acid, cyclamic acid, decanoic acid, dodecyl sulfate, ethane-1,2-disulfonic acid, ethanol Examples include sulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glycerophosphate, glycolic acid, hippuric acid, isobutyric acid, lactobionic acid, lauric acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oleic acid, palmitic acid, pamoic acid, pyroglutamic acid, sebacic acid, stearic acid, and undecylenic acid.
[0141] Preferably, the organic acid is selected from the group consisting of citric acid, malic acid, lactic acid, benzoic acid, tartaric acid, and mixtures thereof. In some preferred embodiments, the organic acid is citric acid or a salt thereof, or comprises citric acid or a salt thereof.
[0142] In some embodiments, the product contains an alkali metal salt of an organic acid. For example, at least a portion of the organic acid may be present in the product in the form of an alkali metal salt. Suitable alkali metal salts include lithium, sodium, and potassium. In some embodiments, the alkali metal is sodium or potassium. In some embodiments, the alkali metal is sodium. In some embodiments, the product contains an organic acid and a sodium salt of the organic acid. In some embodiments, the organic acid is sodium citrate (such as trisodium citrate) or contains sodium citrate (such as trisodium citrate).
[0143] In some preferred embodiments, the organic acid is or comprises citrate anhydride.
[0144] The amount of organic acids present in the product may vary. An oral product may contain about 0.01% to about 10% by weight of organic acids (e.g., citric acid or its salts) present as one or more organic acids, based on the total weight of the oral product. In some embodiments, an oral product may contain at least about 0.01% by weight, at least about 0.1% by weight, about 0.2% by weight, about 0.3% by weight, about 0.4% by weight, about 0.5% by weight, about 0.6% by weight, about 0.7% by weight, about 0.8% by weight, about 0.9% by weight, about 1% by weight, about 2% by weight, about 3% by weight, about 4% by weight, about 5% by weight, about 6% by weight, about 7% by weight, about 8% by weight, about 9% by weight, or at least about 10% by weight of organic acids, based on the total weight of the oral product. In some preferred embodiments, an oral product may contain about 0.01% to about 5% by weight of organic acids (e.g., citric acid or its salts), based on the weight of the oral product. For example, oral products contain organic acids in amounts ranging from approximately 0.1% to 2.5% by weight of the oral product. If a salt of the organic acid is added (e.g., citrate anhydride), the weight percentage is calculated based on the weight of the free acid, excluding any counterions that may be present.
[0145] In certain embodiments, the organic acid content is sufficient to provide a product pH of about 4.0 to about 9.0, for example, about 4.5 to about 7.0, or about 5.5 to about 7.0, about 4.0 to about 5.5, or about 7.0 to about 9.0. In some embodiments, the organic acid content is sufficient to provide a product pH of about 4.5 to about 6.5, for example, from about 4.5, about 5.0, or about 5.5 to about 6.0, or about 6.5. In some embodiments, the organic acid is provided in an amount sufficient to provide a product pH of about 5.5 to about 6.5, for example, from about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, or about 6.0 to about 6.1, about 6.2, about 6.3, about 6.4, or about 6.5.
[0146] In other embodiments, mineral acids (e.g., hydrochloric acid, sulfuric acid, phosphoric acid, etc.) are added to adjust the product pH to a desired value.
[0147] Organic acids (e.g., citric acid) can be added as is (i.e., as a solid) or in solution, such as water. In some embodiments, the organic acid is added as a 50% aqueous solution.
[0148] salt The oral product may further contain salts, which may be present in an amount sufficient to provide the product with the desired sensory attributes. Non-limiting examples of suitable salts include sodium chloride, potassium chloride, ammonium chloride, flour salt, sodium acetate, and sodium citrate. The salt may be present in any suitable amount of at least about 0.5% by weight of the oral product, e.g., at least about 1% by weight, e.g., at least about 1.5% by weight. In some embodiments, the oral product may contain salts in amounts ranging from about 0.5% to about 10% by weight, e.g., about 1% to about 7.5% by weight, e.g., about 1.5% to about 5% by weight, based on the total weight of the oral product.
[0149] Thickening agent In some embodiments, oral products may contain thickeners. Suitable thickeners may include hydrophilic colloids such as xanthan gum, guar gum, konjac gum, tragacanth gum, and gum arabic. For example, xanthan gum is understood to be a thickener that thickens a composition when added during low-temperature processing (i.e., when no heat is applied).
[0150] If present, a thickening agent (e.g., xanthan gum) may be included in the oral product in an amount of about 0.001% to about 5% by weight, preferably about 0.01% to about 1% by weight.
[0151] Coloring agents Colorants may be used in amounts sufficient to provide the desired physical attributes. Examples of colorants include caramel colorants and various dyes and pigments such as titanium dioxide. Natural colorants such as curcumin, beet juice extract, and spirulina, as well as various synthetic pigments, may also be used. The amount of colorant used in oral products may vary, but if present, it is typically up to about 3% by weight, for example, about 0.1% by weight, about 0.5% by weight, or from about 1% to about 3% by weight, based on the total weight of the oral product.
[0152] Other additives Other ingredients such as preservatives (e.g., potassium sorbate), disintegrants (e.g., croscarmellose sodium, crospovidone, sodium starch glycolate, pregelatinized corn starch, etc.), and / or antioxidants may also be used. Typically, such ingredients, when used, are used in amounts up to about 10% by weight of the oral product, e.g., at least about 0.1% by weight, e.g., about 0.5% to about 10% by weight. Disintegrants may be used in amounts sufficient to provide control over the desired physical attributes of the oral product, for example, by providing loss of physical integrity and dispersibility of various component materials upon contact between the formulation and water (e.g., by undergoing swelling upon contact with water).
[0153] Examples of further types of additives include zinc or magnesium salts, or combinations thereof, selected to be relatively water-soluble with respect to compositions with higher water solubility (e.g., magnesium gluconate or zinc gluconate), or selected to be relatively water-insoluble with respect to compositions with reduced water solubility (e.g., magnesium oxide or zinc oxide). See, for example, U.S. Patent No. 9,237,769 by Mua et al., U.S. Patent No. 7,861,728 by Holton, Jr. et al., U.S. Patent Application Publication No. 2010 / 0291245 by Gao et al., and U.S. Patent Application Publication No. 2007 / 0062549 by Holton, Jr. et al. (each of which is incorporated herein by reference), for representative components, combinations of components, relative amounts of these components, and forms and methods for using these components. The typical range of such additional additives can vary depending on the properties and functions of the additive, as well as the intended effect on the final product, and may range, for example, from about 10% by weight (e.g., about 0.1% to about 5% by weight) based on the total weight of the oral product.
[0154] In some embodiments, the oral product contains a magnesium salt. A non-limiting example of a suitable magnesium salt is magnesium gluconate. In some embodiments, the oral product contains magnesium in an amount of about 0.1% to about 2% by weight, or about 0.2% to about 1% by weight, based on the element magnesium.
[0155] In some preferred embodiments, the oral product comprises zinc or zinc gluconate. In some embodiments, the oral product comprises zinc or zinc gluconate in an amount of about 0.1% to about 2% by weight, or about 0.1% to about 1% by weight, based on the oral product.
[0156] The aforementioned additives can be used together (for example, as an additive formulation) or separately (for example, individual additive components can be added at different stages involved in the preparation of the final product). Furthermore, the aforementioned types of additives may be encapsulated so as to be provided in the final product or composition. Exemplary encapsulated additives are described, for example, in Atchley's International Publication 2010 / 132444, which is previously incorporated herein by reference.
[0157] Oral products The products or compositions described herein are configured for oral use. As used herein, “configured for oral use” means that the product is provided in such a form that, during use, the saliva in the user’s mouth allows one or more components of the product (e.g., the active ingredient) to pass through the user’s mouth. In certain embodiments, the product is adapted to deliver the active ingredient and optionally flavoring agents to the user through the mucous membranes of the user’s mouth, the user’s digestive system, or both. In some examples, the active ingredient and optionally flavoring agents may be absorbed through the mucous membranes of the mouth or through the digestive tract when the product is used.
[0158] In some embodiments, the oral product contains the combination of active ingredients in an amount of at least about 0.01% by weight of the oral product, for example, at least about 0.1% by weight, or preferably at least about 1% by weight. The oral product may contain, for example, an amount of the combination of active ingredients of at least about 0.25% by weight, at least about 0.3% by weight, at least about 0.5% by weight, at least about 0.75% by weight, at least about 1% by weight, at least about 1.5% by weight, at least about 2% by weight, at least about 3% by weight, at least about 4% by weight, or at least about 5% by weight of the oral product. The combination of active ingredients may be present in an amount of about 50% by weight or less of the oral product, for example, about 40% by weight or less, for example, about 30% by weight or less, for example, about 20% by weight or less, for example, about 10% by weight or less.
[0159] The combination of active ingredients may be present in an amount of about 0.01% to about 20% by weight. For example, the combination of active ingredients may be present in an amount of about 0.05% to about 15% by weight of the oral product, for example, about 0.1% to about 10% by weight, or about 0.5% to about 5% by weight. Preferably, the combination of active ingredients is present in an amount of about 0.1% to about 10% by weight of the oral product. Preferably, the combination of active ingredients is present in an amount of about 0.5% to about 5% by weight of the oral product, more preferably about 1% to about 5% by weight.
[0160] In some embodiments, the combination of active ingredients may be present in an amount of about 1.5% to about 20% by weight of the oral product, for example, about 2.5% to about 15% by weight, for example, about 5% to about 10% by weight.
[0161] Oral products can take any form suitable for application to the oral cavity of humans or animals. In some embodiments, oral products are in solid oral dosage form.
[0162] The oral products described herein may take various forms, including lozenges or chews.
[0163] Solid oral dosage form As described herein, oral products are in solid form. As used herein, the term “solid” means that the product can substantially maintain its physical shape when not supported by external means, such as packaging. Thus, a product can be considered solid, solid-like, solid-form, or solid-like-form at room temperature. To avoid misunderstanding, a solid product remains substantially solid up to 30°C. In some embodiments, an oral product is in solid form, such as in the form of a chew or lozenge. In some embodiments, an oral product is a chew or lozenge. In some embodiments, an oral product may be a chewing gum product. In some embodiments, an oral product is a chew.
[0164] The oral products disclosed herein can be formed into a variety of shapes, including pills, tablets, spheres, strips, films, sheets, coins, cubes, beads, oval shapes, obloids, cylinders, bean shapes, sticks, or rods. The cross-sectional shapes of the products can vary, with typical cross-sectional shapes including circular, square, elliptical, and rectangular shapes. Such shapes can be formed in a variety of ways using devices such as moving belts, nips, extruders, granulation devices, and compression devices.
[0165] In some embodiments, the solid oral product is a form selected from the group consisting of chews or lozenges.
[0166] In other embodiments, the oral product is in solid form, such as loose wet snuff, loose dry snuff, chewing tobacco form, pelletized pieces, extruded or molded strips, pieces, rods or sticks, finely ground powder, powdered pieces and finely ground or pulverized aggregates of components, flake-like pieces, molded pieces, gum, film, film or strip that readily dissolves or disperses in water, capsule-like material, tablets, lozenges, etc. In some embodiments, the oral product is a tablet or lozenge. In some embodiments, the oral product may be a chewing gum product. In some embodiments, the oral product is in the form of wet snuff or snus and may or may not contain tobacco.
[0167] Chu In some embodiments, the product may be chewable, meaning that the product has a mild elasticity or "bounciness" when chewed and possesses a desired degree of malleability. The chewable product may dissolve completely, or it may be in the form of an insoluble gum in which only certain components (e.g., active ingredients, flavorings, sweeteners) dissolve, leaving an insoluble matrix. In a preferred embodiment, the product is in a completely dissolvable chewable form.
[0168] As described herein, “Chew” is a confectionery-type product that can be chewed by the user before dissolving in the mouth (i.e., a dissolvable chew), or it may be chewing gum. Preferably, the “Chew” dissolves completely in the user’s mouth. The product may be dissolvable. Where used herein, the terms “dissolve,” “dissolve,” and “solubility” refer to a product having water-soluble components that interact with moisture in the oral cavity to enter a solution, thereby causing gradual ingestion of the product. According to one embodiment, a solubility product may remain in the user’s mouth for a predetermined time until it is completely dissolved. The dissolution rate can vary over a wide range from about 1 minute or less to about 60 minutes. For example, a rapid-release product typically dissolves and / or releases the desired components (e.g., active ingredients, flavors, etc.) in about 2 minutes or less, often about 1 minute or less (e.g., about 50 seconds or less, about 40 seconds or less, about 30 seconds or less, or about 20 seconds or less). Dissolution can occur by any means, including melting, mechanical destruction (e.g., chewing), enzymatic or other chemical degradation, or disruption of interactions between the components of the product.
[0169] In other embodiments, the product does not dissolve while it remains in the user's mouth.
[0170] Chew generally contains a binder such as natural gum, pectin, agar, carrageenan, or starch, or a combination thereof. In some embodiments, the binder contains or is pectin.
[0171] In some embodiments, the chewable product (i.e., "Chew") comprises a combination of active ingredients, a sugar alcohol, or at least one sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar, and at least one binder. In some embodiments, the chewable product (i.e., "Chew") comprises about 0.1% to about 10% by weight of the oral product of a combination of active ingredients, a sugar alcohol, or at least one sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar, and at least one binder. The chewable product or Chew may also optionally contain sweeteners and / or flavorings.
[0172] Typical chew compositions and products may incorporate, based on the total weight of the oral product, a combination of active ingredients in an amount of about 0.1% to about 20% by weight, a binder (e.g., pectin, agar, carrageenan, starch, or a combination thereof) in an amount of about 0.1% to about 10% by weight, and at least one filler selected from the group consisting of at least 30% by weight of sugar alcohols, or at least one sugar, or a combination of at least one sugar alcohol and at least one sugar. Optionally, the oral product may further contain, based on the total weight of the oral product, a sweetener in an amount of about 0.01% to about 2% by weight, and / or at least one flavoring agent in an amount of about 0.1% to about 10% by weight. The specific proportions and selections of ingredients vary depending on the desired flavor, texture, and other characteristics. For example, a combination of active ingredients may be present in the chew in an amount of about 0.1% to about 10% by weight of the oral product.
[0173] In some embodiments, the oral chewable product contains pectin and an organic acid together with one or more sugar alcohols in an amount of at least 30% by weight of the oral product.
[0174] In some embodiments, the oral chewable product includes at least one extender selected from the group consisting of sugar alcohols, or sugars, or combinations of at least one sugar alcohol and at least one sugar. In some embodiments, the at least one extender is selected from sugar alcohols or sugars. In some embodiments, the at least one extender is selected from sugar alcohols. In some embodiments, the at least one extender is selected from sugars. In some embodiments, the at least one extender is selected from combinations of at least one sugar alcohol and at least one sugar.
[0175] The total amount of the bulking agent (preferably a sugar alcohol) may be at least about 30% by weight of the oral product, for example, at least about 40% by weight, for example, at least about 45% by weight. In some preferred embodiments, the total amount of the bulking agent (preferably a sugar alcohol) may be at least about 50% by weight of the oral product.
[0176] In some embodiments, the total amount of the bulking agent (preferably a sugar alcohol) is present in an amount of about 30% to about 99% by weight of the oral product, for example, about 40% to about 99% by weight, for example, about 45% to about 99% by weight, for example, about 50% to about 99% by weight, for example, about 60% to about 95% by weight, and preferably about 70% to about 90% by weight. It is preferable that the bulking agent (preferably a sugar alcohol) is present in an amount of about 80% to about 95% by weight of the oral product.
[0177] In some preferred embodiments, the total amount of the bulking agent (preferably a sugar alcohol) is present in an amount of about 40% to about 60% by weight of the oral product.
[0178] Alternatively, in some preferred embodiments, the total amount of the bulking sugar alcohol is about 50% to about 90% by weight of the oral product. In such embodiments, the bulking agent may consist of sugar alcohols.
[0179] The sugar alcohol may be selected from the group consisting of isomalt, erythritol, sorbitol, arabitol, ribitol, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, or mixtures thereof. In some embodiments, the sugar alcohol is selected from the group consisting of maltitol, sorbitol, erythritol, mannitol, lactitol, xylitol, isomalt, and mixtures thereof. In some embodiments, the sugar alcohol is selected from the group consisting of maltitol, isomalt, and mixtures thereof. In some embodiments, the sugar alcohol is isomalt or contains isomalt. In some embodiments, the sugar alcohol is maltitol or contains maltitol. In some embodiments, the sugar alcohol includes a combination of isomalt and maltitol.
[0180] In some embodiments, the sugar substitute may be a substitute for a sugar alcohol, or may be used in combination with one or more sugar alcohols. Suitable sugar substitutes include allulose, soluble tapioca fiber, inulin, and combinations thereof.
[0181] In some embodiments, sugars may be included as a substitute for sugar alcohols or used in combination with one or more sugar alcohols. If present, sugars may be in the form of glucose, fructose, galactose, sucrose, or mixtures thereof. In some embodiments, the oral chewing product contains sugar (e.g., sucrose) in combination with at least one sugar alcohol (e.g., maltitol and / or isomalt). Sugars may be present in any preferred amount, such as 10% to about 50% by weight of the oral product, for example, about 20% to about 40% by weight.
[0182] In some embodiments, the bulking agent comprises at least one sugar alcohol selected from maltitol and / or isomalt and sucrose. In some embodiments, at least one bulking agent comprises maltitol and sucrose. In some embodiments, at least one bulking agent comprises isomalt and sucrose.
[0183] In some embodiments, the bulking agent includes a combination of maltitol and sugar. Maltitol may be present in an amount of about 20% to about 50% by weight of the oral product, and sugar may be present in an amount of about 10% to about 50% by weight.
[0184] In some embodiments, the bulking agent includes a combination of isomalt and sugar. The isomalt may be present in an amount of about 20% to about 50% by weight of the oral product, and the sugar may be present in an amount of about 10% to about 50% by weight.
[0185] In some embodiments, the binder is selected from the group consisting of pectin, agar, carrageenan, starch, and mixtures thereof. In some preferred embodiments, the binder is pectin or contains pectin. In some embodiments, the binder (e.g., pectin) is present in an amount of about 0.1% to about 10% by weight of the oral product. Preferably, the binder (e.g., pectin) is present in an amount of about 1% to about 5% by weight of the oral product.
[0186] Oral products may also contain organic acids, gelling agents, or both to crosslink pectin.
[0187] In some embodiments, the oral chewing product contains an acidifying agent. The acidifying agent may be an organic acid or an inorganic acid. The organic acid may be any suitable organic acid. Suitable organic acids are as described in the section titled “Additives” above. For example, the organic acid may be selected from the group consisting of citric acid, malic acid, lactic acid, benzoic acid, tartaric acid and mixtures or salts thereof. In preferred embodiments, the organic acid is citric acid and / or a salt thereof. The organic acid may include, for example, a combination of citric acid and a salt of citric acid (e.g., a sodium salt).
[0188] The oral products of this disclosure in the form of a chew may contain varying amounts of water. For example, the water content of the chew product may be provided within a specific range to define the final form of the product. The water content of the chew products described herein may vary within such range according to desired properties and characteristics, in addition to defining the final form of the product before use by the consumer of the product. For example, the chew product may have a water content ranging from about 0.1% to about 20% by weight of the oral product, for example, from about 1% to about 10% by weight.
[0189] Oral products in chew form are (a) A combination of the active ingredients described herein in an amount of about 0.1% to about 10% by weight of the oral product, (b) At least one bulking agent selected from the group consisting of sugar alcohols, or sugars, or combinations of at least one sugar alcohol and at least one sugar, wherein the total amount of sugar alcohols and / or sugars is about 40% to about 99% by weight of the oral product, (c) At least one binder in an amount of about 0.1% to about 10% by weight of the oral product, Depending on the circumstances, (d) may include flavoring agents, organic acids and / or sweeteners.
[0190] Oral products in chew form are (a) A combination of the active ingredients described herein in an amount of about 0.1% to about 10% by weight of the oral product, (b) At least one bulking agent selected from the group consisting of sugar alcohols, or sugars, or combinations of at least one sugar alcohol and at least one sugar, wherein the total amount of sugar alcohols and / or sugars is about 40% to about 99% by weight of the oral product, (c) At least one binder in an amount of about 0.1% to about 10% by weight of the oral product, (d) Organic acids in an amount of approximately 0.1% to approximately 5% by weight of the oral product, Depending on the circumstances, it may include (e) flavoring agents and / or sweeteners.
[0191] Oral products in chew form are (a) A combination of the active ingredients described herein in an amount of about 0.1% to about 10% by weight of the oral product, (b) at least one sugar alcohol, wherein the total amount of sugar alcohols is about 50% to about 90% by weight of the oral product, and at least one sugar alcohol is selected from the group consisting of isomalt, maltitol and mixtures thereof. (c) At least one binder in an amount of about 0.1% to about 10% by weight of the oral product, which is pectin or contains pectin, Depending on the circumstances, (d) may include flavoring agents, organic acids and / or sweeteners.
[0192] Oral products in chew form are (a) A combination of the active ingredients described herein in an amount of about 0.1% to about 10% by weight of the oral product, (b) at least one sugar alcohol, which may be combined with sugar, wherein the total amount of sugar alcohols is about 40% to about 60% by weight of the oral product, and at least one sugar alcohol is maltitol or contains maltitol, (c) At least one binder in an amount of about 0.1% to about 10% by weight of the oral product, which is pectin or contains pectin, Depending on the circumstances, (d) may include flavoring agents, organic acids and / or sweeteners.
[0193] In some embodiments, the combination of active ingredients in the oral chewable product includes (i) caffeine, (ii) a combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12, (iii) taurine, and (v) ginseng. The combination of active ingredients in the oral chewable product may include (i) caffeine, (ii) a combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12, (iii) taurine, (iv) vitamin C, and (v) ginseng.
[0194] Oral chewable products may have a weight of approximately 0.1g to approximately 10g, for example, approximately 0.5g to approximately 5g. Preferably, oral chewable products have a weight of approximately 1g to approximately 5g. An exemplary chewable product may have a weight of approximately 4g.
[0195] Oral chewable products (for example, having a total weight of about 1 g to about 5 g) may contain an amount of caffeine of about 1 mg to about 250 mg, preferably about 10 mg to about 200 mg or about 10 mg to about 100 mg, more preferably about 20 mg to about 50 mg.
[0196] Oral chewable products (for example, having a total weight of about 1 g to about 5 g) may contain an amount of taurine of about 1 mg to about 200 mg, preferably about 5 mg to about 100 mg or about 5 mg to about 50 mg, more preferably about 10 mg to about 25 mg.
[0197] Oral chewable products (for example, having a total weight of about 1 g to about 5 g) may contain a total amount of B vitamins of about 0.1 mg to about 100 mg, preferably about 1 mg to about 50 mg, and more preferably about 1 mg to about 25 mg. In some embodiments, the B vitamins in an oral chewable product (for example, having a total weight of about 1 g to about 5 g) consist of a combination of vitamins B2, B3, B6, B9, and B12, and the total amount of B vitamins is about 1 mg to about 25 mg.
[0198] If present, an oral chewable product (for example, having a total weight of about 1 g to about 5 g) may contain an amount of ginseng of about 0.01 mg to about 5 mg, preferably about 0.01 mg to about 2 mg, more preferably about 0.01 mg to about 1 mg. The amount of ginseng in an oral chewable product may be about 2 mg or less, for example, about 1 mg or less, for example, about 0.1 mg or less. The amount of ginseng in an oral chewable product may be about 0.01 mg to about 1 mg.
[0199] If present, an oral chewable product (e.g., having a total weight of about 1 g to about 5 g) may contain an amount of vitamin C of about 1 mg to about 300 mg, for example, about 10 mg to about 200 mg. In some preferred embodiments, an oral chewable product (e.g., having a total weight of about 1 g to about 5 g) may contain an amount of vitamin C of about 25 mg to about 100 mg.
[0200] In some embodiments, the oral chewable product (for example, having a total weight of about 1g to about 5g) (i) Approximately 1 mg to 250 mg of caffeine, (ii) A combination of B vitamins, including at least 0.1 mg to 100 mg of vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12, and (iii) Taurine in amounts of approximately 1 mg to 200 mg (iv) Approximately 1 mg to 300 mg of vitamin C, and / or Depending on the case, (v) may contain approximately 0.01 mg to 5 mg of ginseng.
[0201] In some embodiments, the oral chewable product (for example, having a total weight of about 1g to about 5g) (i) Approximately 10 mg to 100 mg of caffeine, (ii) A combination of B vitamins, including at least 1 mg to 25 mg of vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12, and (iii) Taurine, approximately 5 mg to 50 mg (iv) Approximately 25 mg to 100 mg of vitamin C, and / or Depending on the case, (v) may contain approximately 0.01 mg to 5 mg of ginseng.
[0202] In some embodiments, the oral chewable product (for example, having a total weight of about 1g to about 5g) (i) Approximately 10 mg to 100 mg of caffeine, (ii) A combination of B vitamins, including at least 5 mg to 25 mg of vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12, and (iii) Taurine, approximately 5 mg to 50 mg (iv) Approximately 25 mg to 100 mg of vitamin C, and / or Depending on the case, (v) may contain approximately 0.01 mg to 5 mg of ginseng.
[0203] In some embodiments, the oral chewable product (for example, having a total weight of about 1g to about 5g) (i) Approximately 10 mg to 100 mg of caffeine, (ii) A combination of B vitamins, including at least 1 mg to 25 mg of vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12. (iii) Taurine, approximately 5 mg to 50 mg (iv) Approximately 25 mg to 100 mg of vitamin C, (v) Contains approximately 0.01 mg to 5 mg of ginseng.
[0204] In some embodiments, the oral chewable product (for example, having a total weight of about 1g to about 5g) (i) Approximately 10 mg to 100 mg of caffeine, (ii) A combination of B vitamins, including at least 5 mg to 25 mg of vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12. (iii) Taurine, approximately 5 mg to 50 mg (iv) Approximately 25 mg to 100 mg of vitamin C, (v) Contains approximately 0.01 mg to 5 mg of ginseng.
[0205] The inventors have found that the amounts of the active ingredients described above provide beneficial effects such as increasing energy levels and enhancing brain function, while also providing a safe product with reduced side effects. The amounts can be adjusted to ensure high efficacy while guaranteeing consumer safety and avoiding any excessive intake of the active ingredients.
[0206] In any of the embodiments described above, the combination of active ingredients in the oral chewable product may optionally further contain magnesium glycinate in an amount of about 0.1% to about 10% by weight of the oral product, for example, about 0.5% to about 5% by weight, or about 0.5% to about 1% by weight. If present, the amount of magnesium glycinate in the oral chewable product may be about 1 mg to about 50 mg, preferably about 10 mg to about 30 mg.
[0207] Oral chewing products may contain any further suitable additives. Suitable additives are described in more detail above, and all additives described herein may be included in oral chewing products. In some embodiments, oral chewing products may further contain additives selected from the group consisting of flavoring agents, sweeteners, acidifiers, preservatives, and mixtures thereof. Examples of each of these forms of additives are described above herein.
[0208] In some embodiments, the choux may further include a coating, such as a coating oil. The coating may include oils or waxes, such as sunflower oil and / or carnauba wax. Suitable coatings are described in more detail with respect to the lozenge product, and this description applies equally to the choux.
[0209] For example, the tubing may be coated with an overcoat material. Devices for providing an outer coating layer to a compressed pelletized composition are available from Thomas Engineering as CompuLab 24, CompuLab 36, Accela-Cota 48, and Accela-Cota 60.
[0210] If present, the coating may include a film-forming polymer such as a cellulosic polymer, any plasticizer, and any flavorings, colorants, salts, sweeteners, or other additives of the kinds described herein. The coating composition may be essentially aqueous and can be applied using any pellet or tablet coating technique known in the art, such as bread coating. Typical film-forming polymers include cellulose polymers such as methylcellulose, hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose, and carboxymethylcellulose. Typical plasticizers include aqueous solutions or emulsions of glyceryl monostearate and triethyl citrate. Additional potential coatings include food-grade shellac, oils such as sunflower oil, waxes such as carnauba wax, and combinations thereof.
[0211] lozenges In some embodiments, the products disclosed herein may be in the form of a soluble, lightly chewable lozenge product for oral use. As used herein, the term “lozenge” refers to a soluble oral product prepared by solidifying a liquid or gel composition, such as a composition containing a gelling agent or binder, so that the final product becomes a solidified solid gel. Alternatively, the lozenge product may be called a soft lozenge. In certain embodiments, the lozenge products of this disclosure are characterized by cohesiveness sufficient to withstand light chewing action in the oral cavity without rapidly disintegrating. The lozenge products of this disclosure typically do not exhibit the highly deformable chewing quality found in conventional chewing gum. For example, the following are described in U.S. Patents No. 9,204,667 and 9,775,376 of Cantrell et al. and No. 10,357,054 of Marshall et al., which are incorporated herein by reference: Smokeless tobacco lozenges, lozenge formulations, lozenge composition, lozenge characteristics, and techniques for formulating or manufacturing lozenges. Certain products may exhibit one or more of the following characteristics, for example: crunchy, granular, chewy, syrupy, paste-like, fluffy, smooth, and / or creamy. In certain embodiments, desired texture characteristics may be selected from the group consisting of adhesiveness, cohesiveness, density, dryness, fragility, granularity, gumminess, hardness, weight, hygroscopicity, hygroscopicity, mouth coating, roughness, slipperiness, smoothness, viscosity, wettability, and combinations thereof.
[0212] The lozenge products of this disclosure typically comprise a combination of active ingredients, binders, and sugar alcohols and / or sugars (e.g., as filler components) in an amount of about 0.1% to about 10% by weight of the oral product. Any active ingredient discussed herein is intended to be suitable for use as an active ingredient in the lozenge products of this disclosure.
[0213] In some embodiments, the active ingredients may be provided in the lozenge in liquid form or in dry powder or particle form. In some embodiments, each active ingredient included in the combination of active ingredients is provided in dry powder form within the lozenge.
[0214] A binder (or a combination of two or more binders) may be used in the product in an amount sufficient to provide the lozenge product with the desired physical attributes and physical integrity. In some embodiments, the binder in the lozenge may include pectin or gum. A typical amount of the binder (e.g., pectin or gum) may constitute at least about 5% or at least about 10% of the total weight of the lozenge product. In certain embodiments, the binder (e.g., pectin or gum) may be present in an amount of at least about 30% by weight, at least about 35% by weight, at least about 40% by weight, at least about 45% by weight, or at least about 50% by weight, based on the total weight of the oral product. In some embodiments, the binder (e.g., pectin or gum) may be present in an amount of about 35% to about 55% by weight of the oral product. Preferably, the total amount of the binder (e.g., pectin or gum) in the lozenge product will not exceed about 55% by weight of the oral product. In most cases, the amount of binder (e.g., pectin or gum) in the desired product will not exceed approximately 65% by weight of the oral product, and often not exceed approximately 60% by weight.
[0215] In some embodiments, the binder may include pectin, or may be pectin. The lozenge product may contain pectin as the sole binder, or pectin may be included in combination with gum.
[0216] In certain embodiments, the binder is or comprises gum. The gum may include natural gum. In particular, natural gum (e.g., gum arabic) may be incorporated into lozenge products as a softening agent. Advantageously, the use of natural gum as a softening agent provides the desired texture quality necessary to form lozenge products such as those described herein. It should be noted that increasing the amount of natural gum (e.g., gum arabic) and then decreasing the amount of sugar alcohols and / or sugars can advantageously increase the flexibility of the resulting lozenge product. As used herein, natural gum refers to naturally occurring polysaccharide materials useful as softening agents. Typical natural gums of plant origin that are typically somewhat water-soluble include xanthan gum, guar gum, gum arabic, ghati gum, tragacanth gum, karaya gum, locust bean gum, gellan gum, and combinations thereof. Preferably, gum arabic may be used as an exemplary natural gum that provides the above-mentioned softening properties when incorporated into the lozenge products of this disclosure.
[0217] As described above, the lozenge products of the present disclosure may comprise at least one sugar, or at least one sugar alcohol, or a combination of at least one sugar and at least one sugar alcohol (e.g., in the form of a filler component). Sugar alcohols are particularly advantageous as filler components in the lozenges of the present disclosure because such materials contribute some sweetness and do not disrupt the desired chewable characteristics of the final product. In some embodiments, the sugar alcohol may be selected from the group consisting of maltitol, sorbitol, erythritol, mannitol, lactitol, xylitol, and isomalt. In some embodiments, isomalt may be incorporated as the sole filler component. Sugar alcohols and / or sugars are typically added to the products of the present disclosure in the form of aqueous solutions or suspensions, such as solutions or suspensions having a solid content of about 50% to about 90% by weight. Combinations of sugar alcohols and / or sugars with further filler components can also be used. Filler components often perform multiple functions, such as improving certain sensory stimuli such as texture and mouthfeel, and improving the cohesiveness or compressibility of the product. In some embodiments, the filler includes sugar substitutes such as allulose, soluble tapioca fiber, and inulin, one or more of these. Such sugar substitutes may be substitutes for sugar alcohols, or may be used in combination with one or more sugar alcohols.
[0218] Molten material In some embodiments, the product may be meltable, for example, as described in U.S. Patent Application Publication 2012 / 0037175 by Cantrell et al., which is incorporated herein by reference in its entirety.
[0219] As used herein, “meltable,” “meltable,” and “meltable” refer to the ability of a product to change from a solid state to a liquid state. That is, melting occurs when a substance (e.g., the products disclosed herein) changes from a solid to a liquid, usually by the application of heat.
[0220] The application of heat to the products disclosed herein is provided by the temperature of the user's mouth. Therefore, the term “meltable” refers to a product that can be liquefied in the user's mouth when the product undergoes a phase change from solid to liquid, and is intended to distinguish between a product that simply disintegrates in the mouth due to the loss of cohesiveness within the product and a product that simply dissolves in the mouth as its water-soluble components interact with moisture.
[0221] Generally, meltable products contain lipids. In some embodiments, the composition contains lipids. Lipids are typically fats, oils, or waxy substances derived from animal or plant materials (e.g., plant fats), and typically contain mostly triglycerides, along with smaller amounts of free fatty acids and mono or diglycerides. In certain embodiments, the lipids are solid or semi-solid at room temperature (i.e., 25°C) and can at least partially liquefy (i.e., “melt”) when exposed to the temperature of the user’s mouth. Exemplary plant fats consist mainly of saturated or unsaturated fatty acid chains (mostly bonded within triglyceride structures) having carbon lengths of about 10 to about 26 carbon atoms, or about 14 to about 20 carbon atoms, or about 14 to about 18 carbon atoms.
[0222] In some embodiments, lipids include oils, particularly food-grade oils including fractionated oils. Such oils include vegetable oils (e.g., acai oil, almond oil, amaranth oil, apricot oil, apple seed oil, argan oil, avocado oil, babassu oil, beech nut oil, bean oil, bitter melon oil, black seed oil, blackcurrant seed oil, borage seed oil, born tallow nut oil, bottle gourd oil, Brazil nut oil, buffalo pumpkin oil, butternut squash seed oil, cap chestnut oil, canola oil, carob cashew oil) - Oils, cocoa butter, burdock oil, coconut oil, corn oil, cosne oil, coriander seed oil, cottonseed oil, date oil, jika oil, eggplant seed oil, evening primrose oil, camelina oil, linseed oil, grape seed oil, grapefruit seed oil, hazelnut oil, hemp oil, kapok seed oil, kenaf seed oil, larlemanthia oil, lemon oil, linseed oil, macadamia oil, muffler oil, marula oil, meadowfoam seed oil, mongongo nut oil, mustard oil Niger seed oil, nutmeg butter, okra seed oil, olive oil, orange oil, palm oil, papaya seed oil, peanut oil, pecan oil, perilla seed oil, oyster seed oil, pecan oil, pili nut oil, pine seed oil, pistachio oil, pomegranate seed oil, poppy seed oil, pracaxi oil, prune kernel oil, pumpkin seed oil, quinoa oil, ramuchil oil, rapeseed oil, rice bran oil, royal oil, thatcha inchi oil, safflower oil, sapote oil, sage oil, sesame oil, shea butter Examples of oils include, but are not limited to, soybean oil, sunflower oil, tarami oil, tea seed oil, thistle oil, tiger nut oil, tobacco seed oil, tomato seed oil, walnut oil, watermelon seed oil, wheat germ oil, and combinations thereof), animal oils (e.g., bovine fat, buffalo fat, sheep fat, goat fat, porcine fat, lard, camel fat, animal fat, liquid margarine, fish oil, fish liver oil, whale oil, seal oil, and combinations thereof), and mineral oils.
[0223] In certain embodiments, the plant-derived fats of this disclosure include palm oil, palm kernel oil (including fractionated palm oil), soybean oil, cottonseed oil, and mixtures thereof. In one embodiment, the lipid is a blend of palm oil and palm kernel oil. The lipid may be, for example, hydrogenated, partially hydrogenated, or unhydrogenated. Exemplary embodiments of the lipid can be purchased from Aarhus Karlshamn USA Inc. under the trademarks CEBES®, CISAO®, or CONF AO®.
[0224] The melting point of lipids is typically above about 29°C, for example, about 29°C to about 49°C, or about 36°C to about 45°C, or about 38°C to about 41°C. In some embodiments, the use of lipids with a melting point below about 36°C is not advantageous due to melting that may occur during product storage or handling. One test for determining the melting point of lipids is the Mettler dropping point method (ASTM D3954-15, Standard Test Method for Dropping Point of Waxes, ASTM International (West Conchohocken, Pennsylvania), 2015, www.astm.org).
[0225] If present, the amount of lipids in the composition may vary. In certain embodiments, the amount of lipids is at least about 10% by weight, at least about 20% by weight, or at least about 30% by weight, based on the dry weight of the composition. In certain embodiments, the amount of lipids is less than about 70% by weight, less than about 60% by weight, or less than about 50% by weight, based on dry weight. Exemplary lipid weight ranges include about 10% by weight to about 70% by weight, for example, about 35% by weight to about 50% by weight, based on dry weight. In some embodiments, the amount of lipids is about 35% by weight, about 40% by weight, about 45% by weight, or about 50% by weight of the total oral product.
[0226] In some embodiments, the oral product contains lipids. In one embodiment, the lipid is an oil selected from the group consisting of palm oil, palm kernel oil, soybean oil, sunflower oil, cottonseed oil, coconut oil, and combinations thereof, wherein the oil may be hydrogenated, partially hydrogenated, or unhydrogenated. In one embodiment, the lipid is a medium-hardness trans-hydrogenated filled fat such as Confao® 5, available from AarhusKarlshamn USA Inc. (131 Marsh Street, Port Newark, New Jersey (07114)).
[0227] In some embodiments, the product in a molten form contains about 35% to about 50% by weight of lipids and about 35% to about 55% by weight of sugar alcohols. In some embodiments, sugar alcohols may include isomalt, erythritol, sorbitol, arabitol, ribitol, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, or combinations thereof. In some embodiments, the sugar alcohol is isomalt or contains isomalt. In some embodiments, the sugar substitute may be a substitute for a sugar alcohol or may be used in combination with one or more sugar alcohols. Suitable sugar substitutes include allulose, soluble tapioca fiber, inulin, and combinations thereof.
[0228] tablet In certain embodiments, the product is in the form of compressed or molded tablets. Exemplary tablet dosage forms have a weight of about 250 mg to about 1500 mg, for example, about 250 mg to about 700 mg, or about 700 mg to about 1500 mg. The tablets may have any of a variety of shapes, including conventional pill or tablet shapes.
[0229] Generally, the tablet-form product contains a glucose-polysaccharide blend and a sugar alcohol. In some embodiments, the glucose-polysaccharide blend is present in an amount of about 35% to about 50% by weight based on the total weight of the product, and the sugar alcohol is present in an amount of about 30% to about 45% by weight based on the total weight of the product. In some embodiments, the sugar alcohol may be isomalt, erythritol, sorbitol, arabitol, ribitol, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, or a combination thereof. In some embodiments, the sugar alcohol is isomalt or contains isomalt.
[0230] Lozenges In some embodiments, the products disclosed herein may be in the form of a soluble lozenge product for oral use. Exemplary lozenge products of the present invention may be in the form of lozenges, tablets, microtabs, or other tablet-type products. For example, U.S. Patent No. 4,967,773 by Shaw, U.S. Patent No. 5,110,605 by Acharya, U.S. Patent No. 5,733,574 by Dam, U.S. Patent No. 6,280,761 by Santus, U.S. Patent No. 6,676,959 by Andersson et al., U.S. Patent No. 6,248,760 and U.S. Patent No. 7,374,779 by Wilhelmsen, U.S. Patent Application Publication 2001 / 0016593 by Wilhelmsen, and U.S. Patent Application Publication 2004 / 01015 by Liu et al. See Patent No. 43, U.S. Patent Application Publication No. 2006 / 0120974 of Mcneight, U.S. Patent Application Publication No. 2008 / 0020050 of Chau et al., U.S. Patent Application Publication No. 2009 / 0081291 of Gin et al., and U.S. Patent Application Publication No. 2010 / 0004294 of Axelsson et al. (these are incorporated herein by reference) for descriptions of nicotine-containing lozenges, lozenge formulations, lozenge forms and compositions, lozenge characteristics, and techniques for formulating or manufacturing lozenges.
[0231] Lozenge products are generally labeled "hard" to distinguish them from soft lozenges (i.e., troches). Hard lozenges are amorphous mixtures of sugars and / or carbohydrates. Hard lozenges are made from aqueous syrup, but the water initially present evaporates as the syrup boils during processing, resulting in a very low moisture content in the final product, for example, 0.5% to 1.5% by weight. To obtain hard, non-sticky lozenges, the temperature of the molten material must reach the hard crack stage, generally within the exemplary temperature range of 149°C to 154°C.
[0232] Lozenge-type products may exhibit translucency or transparency in some embodiments. The desired transparency or translucency of a product can be quantified by any known method. For example, the cloudiness (light scattering) and color (light absorption) of a product can be quantified, respectively, using optical methods such as turbidity measurement (or turbidimetry) and colorimetry. Translucency can also be confirmed by visual inspection, simply by lifting the product to a light source and determining whether light passes through the material or product in a diffuse manner.
[0233] The lozenge-type products of this disclosure can incorporate various different additives in addition to the combination of active ingredients and can be prepared according to various different methods commonly known in the art for preparing lozenge-type products. Exemplary compositions, products, and methods for preparing such products are described in detail below herein.
[0234] The lozenge products of this disclosure typically comprise a composition containing a combination of active ingredients in an amount of less than about 2% by weight, a sugar substitute in an amount of at least about 80% by weight, and a sugar alcohol syrup. Any active ingredients discussed herein are suitable for use as active ingredients in the lozenge products provided herein. In some embodiments, the active ingredients may be provided in liquid form or in dry powder or particle form. As described above, the active ingredient may typically be present in amounts ranging from about 0.1% to about 10% by weight, based on the total weight of the product, for example, about 0.1%, about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, or about 4.5%, to about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, or about 10% by weight. In some embodiments, the active ingredient may be present in an amount of less than about 10% by weight, less than about 9% by weight, less than about 8% by weight, less than about 7% by weight, less than about 6% by weight, less than about 5% by weight, less than about 4% by weight, less than about 3% by weight, less than about 2% by weight, or less than about 1% by weight, based on the total weight of the product.
[0235] In some embodiments, the lozenge product includes a sugar substitute. The sugar substitute is typically provided in a pure solid form (e.g., granular or powdery form). In certain embodiments, the sugar substitute is dry and contains a very low water content. For example, the sugar substitute may contain less than about 5% by weight of water, less than about 3% by weight of water, less than about 2% by weight of water, or less than about 1% by weight of water. In certain embodiments, the sugar substitute can form a glassy matrix. The formation of a glassy matrix is generally characterized by a translucent / transparent appearance.
[0236] Typically, sugar substitutes are substantially non-hygroscopic. Non-hygroscopic materials typically do not absorb, adsorb, and / or retain significant amounts of moisture from the air. Non-hygroscopic materials can offer the advantage of reducing the tendency of lozenge products to stick when exposed to humidity. Sugar substitutes can be materials that do not contain any sugar (i.e., materials that do not contain sucrose) and can be produced naturally or synthetically. Sugar substitutes used in the products described herein can be nutrient-rich or non-nutrient-rich. For example, sugar substitutes are generally sugar alcohols. Sugar alcohols that may be useful according to the present invention include, but are not limited to, erythritol, treitol, arabitol, xylitol, ribotol, mannitol, sorbitol, dulcitol, iditol, isomalt, maltitol, lactitol, polyglycitol, and mixtures thereof. For example, in certain embodiments, the sugar alcohol is selected from the group consisting of erythritol, sorbitol, and isomalt. The amount of sugar substitute in the lozenge product may vary, but is typically at least about 75% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, or at least about 95% by weight of the product.
[0237] In certain embodiments, the sugar substitute comprises one or more sugar alcohols. For example, in one embodiment, the sugar substitute is isomalt.
[0238] In some embodiments, the sugar substitute is one or more of allulose, soluble tapioca fiber, and inulin. Such a sugar substitute may be a substitute for a sugar alcohol, or may be used in combination with one or more sugar alcohols.
[0239] In some embodiments, the lozenge products of this disclosure may comprise syrups, such as sugar syrups or sugar alcohol syrups. As used herein, “sugar alcohol syrup” is intended to refer to a concentrated solution of a sugar alcohol having, for example, more than about 40% solid content, preferably more than about 50% solid content, more than about 60% solid content, more than about 70% solid content, or more than about 80% solid content. Typically, the solid content of a sugar alcohol syrup consists mainly of a specified sugar alcohol (i.e., maltitol syrup typically contains more than about 80% by weight, more than about 85% by weight, or more than about 90% by weight of maltitol on a dry basis). Sugar alcohol syrups are generally prepared by heating an aqueous solution of a sugar alcohol and cooling the mixture to obtain a viscous composition. The resulting syrups are typically characterized by a relatively high concentration of sugar alcohol and relatively high stability (i.e., sugar alcohols typically do not crystallize from solution, for example, at room temperature).
[0240] A syrup, such as a sugar alcohol syrup, can preferably influence the recrystallization of the molten sugar substitute. An example of a sugar alcohol syrup particularly useful according to this disclosure is maltitol syrup. Other sugar alcohol syrups can be used, but are not limited to corn syrup, golden syrup, molasses, xylitol, mannitol, glycerol, erythritol, treitol, arabitol, ribitol, mannitol, sorbitol, dulcitol, iditol, isomalt, lactitol, and polyglycitol syrup. Such sugar alcohol syrups can be prepared or obtained from commercially available sources. For example, maltitol syrup is commercially available from suppliers such as Corn Products Specialty Ingredients. While sugar alcohol syrups may be preferred, in certain embodiments, sugar syrups can be used instead of or in combination with sugar alcohol syrups. For example, in some embodiments, corn syrup, golden syrup, and / or molasses can be used.
[0241] The amount of sugar alcohol syrup added to the lozenge composition mixture is typically the amount necessary to slow down the recrystallization of the sugar substitute in molten form. It should be noted that the amount of sugar alcohol syrup may be varied depending on the composition of the remaining components so that recrystallization is sufficiently slowed in order to provide a material with desired characteristics (e.g., a desired level of translucency / transparency). Thus, although the amount of sugar alcohol syrup may vary, it is typically in the range of about 0.1% to about 2% by weight of the lozenge product mixture, often about 0.5% to about 1.5% by weight, and more often about 1% by weight. In certain embodiments, the amount of sugar alcohol syrup is greater, for example, up to about 2% by weight of the mixture, up to about 5% by weight of the mixture, up to about 10% by weight of the mixture, or up to about 20% by weight of the mixture.
[0242] Typical lozenge compositions and lozenge products may incorporate, based on the total weight of the product, a combination of active ingredients of about 10% by weight or less, about 0.01% to about 2% by weight of artificial sweeteners, about 1% to about 5% by weight of humectants, about 1% to about 5% by weight of natural sweeteners, at least about 80% by weight of sugar substitutes, about 0.1% to about 10% by weight of sugar alcohol syrup, one or more flavorings in an amount of up to about 5% by weight, and up to about 3% by weight of salt. The specific proportions and selection of ingredients will vary depending on the desired flavor, texture, and other characteristics.
[0243] Oral products of this disclosure in the form of lozenges may contain varying amounts of water. The water content of the lozenges described herein may vary within such ranges according to desired properties and characteristics, in addition to defining the final form of the product before consumer use of the product. For example, lozenge-type products typically have a water content ranging from about 0.1% by weight to about 5% by weight of the product. Preferably, the water content of the lozenge product, when present within a single product unit before insertion into the user's mouth, is less than about 5% by weight, less than 3% by weight, less than 2% by weight, or less than 1% by weight of the product. In some embodiments, the water content of the lozenge product described herein may be in the range of about 0.1% by weight to about 5% by weight, about 0.5% by weight to about 3% by weight, or about 1% by weight to about 2% by weight of the product.
[0244] Powder or pouch product In some embodiments, the oral product may be in powder form. The powder may be a free-flowing powder. The powder may be contained in a loose form in a container and thus used in a form similar to a snuff cigarette, where the user picks up the powder from the container and places it in their mouth. Alternatively or additionally, the powder may be incorporated into a moisture-permeable (e.g., saliva-permeable) pouch, similar to a snus-type product. The pouch product may be configured to be inserted into the user's mouth, i.e., it may be a pouch oral product.
[0245] In some embodiments, the products of the Disclosure are in the form of pouched oral products. Such pouched products include the oral products described herein, placed in a hygroscopic container (e.g., a water-permeable pouch or a saliva-permeable pouch). For example, a pouched product may include an oral product in powder form incorporated into a saliva-permeable pouch.
[0246] Such compositions in a breathable pouch form are typically used by placing one pouch containing the composition into the mouth of the subject / user. Generally, the pouch is placed somewhere in the user's mouth, for example, under the lips, in a manner similar to how wet snuff products are generally used. The pouch is preferably not chewed or swallowed. Then, upon exposure to saliva, some of the components of the composition within it (e.g., active ingredients and / or any flavors) pass through, for example, the breathable pouch, providing the user with flavor and satisfaction, and the user does not need to spit out any part of the composition. After about 10 to 60 minutes of use / enjoyment, typically about 15 to 45 minutes, a considerable amount of the composition has been ingested by the human subject, and the pouch can be removed from the human subject's mouth for disposal.
[0247] In some embodiments, the pouch is saliva permeable. This means that the pouch is made of a saliva permeable pouch material. Pouch materials used in oral pouch products are typically dry-laid bonded nonwovens comprising viscose rayon fibers (i.e., regenerated cellulose) and an acrylic polymer that acts as a binder in the nonwoven material and provides heat sealing of the pouch during manufacturing. The pouch material may also contain synthetic fibers (e.g., polyester) in addition to viscose fibers. Viscose nonwoven materials commonly used in smokeless tobacco pouches are similar to the fabrics used in tea bags. Nonwovens are fabrics that are not woven or knitted. Methods for manufacturing nonwoven materials are generally known in the art. Further information on nonwovens can be found in "Handbook of Nonwovens" by S. Russell, Woodhead Pub I. Ltd., 2007. In some embodiments, the pouch material is fleece material. In some embodiments, the pouch material is nonwoven material. In some embodiments, the pouch material is a nonwoven fleece material. In some embodiments, the pouch material includes viscose, such as viscose rayon fibers. In some embodiments, the pouch material includes regenerated cellulose fibers. In some embodiments, the pouch material includes polyester fibers, which may constitute the pouch material or be included in combination with viscose (such as regenerated cellulose fibers).
[0248] In some embodiments, the pouch material includes a binder that provides heat sealing of the pouch during manufacturing. In some embodiments, the pouch material includes an acrylic binder. In some embodiments, the pouch material includes an acrylic binder in combination with viscose and / or polyester fibers.
[0249] Suitable packets, pouches, or containers of the type used in the manufacture of smokeless tobacco products are available under the trade names CatchDry, Ettan, General, Granit, Goteborgs Rape, Grovsnus White, Metropol Kaktus, Mocca Anis, Mocca Mint, Mocca Wintergreen, Kicks, Probe, Prince, Skruf, and TreAnkrare. The composition may be contained and packaged in a pouch in a manner that uses the type of ingredients used in the manufacture of conventional snus-type products. The pouch provides a breathable container of a type that can be considered to have characteristics similar to the mesh-type materials used in the manufacture of tea bags. The ingredients of the composition readily diffuse into the user's mouth through the pouch. Non-limiting examples of preferred types of pouches are described, for example, in U.S. Patent No. 5,167,244 of Kjerstad and U.S. Patent No. 8,931,493 of Sebastian et al., as well as in U.S. Patent Application Publications 2016 / 0000140, 2016 / 0073689, 2016 / 0157515, and 2016 / 0192703 of Sebastian et al., each of which is incorporated herein by reference. The pouches may be supplied as individual pouches, or multiple pouches (e.g., 2, 4, 5, 10, 12, 15, 20, 25, or 30 pouches) may be joined or connected together (e.g., end-to-end) so that a single pouch or individual part can be easily removed for use from the integrated strand or matrix of the pouch.
[0250] Exemplary pouches can be manufactured from materials in such a manner that the pouch undergoes controlled dispersion or dissolution during use by the user. Such pouch materials may take the form of mesh, screen, perforated paper, permeable cloth, etc. For example, a pouch material manufactured from rice paper in a mesh form or perforated rice paper can dissolve in the user's mouth. As a result, the pouch and composition can each be completely dispersed in the user's mouth during normal use conditions, and thus both the pouch and composition can be ingested by the user. Other examples of pouch materials can be manufactured using water-dispersible film-forming materials (e.g., binders such as alginates, carboxymethylcellulose, xanthan gum, pullulan), as well as in combination with materials such as pulverized cellulose (e.g., fine-grained wood pulp). Preferred pouch materials are water-dispersible or soluble, but can be designed and manufactured so that under normal use conditions, a considerable amount of composition contents permeates the pouch material before the pouch loses its physical integrity. If desired, flavorings, disintegrants, and other desired components may be incorporated into the pouch material or applied to the pouch material.
[0251] The amount of oral product contained in each pouched product unit, for example, within a pouch, may vary. In some embodiments, the weight of the composition in each pouch is at least about 50 mg, for example, about 50 mg to about 1 gram (1,000 mg), for example, about 100 mg to about 900 mg, for example, about 200 mg to about 800 mg, for example, about 500 mg to about 700 mg. In some smaller embodiments, the weight of the composition in each pouch may be about 100 mg to about 300 mg. In larger embodiments, the weight of the composition in each pouch may be about 300 mg to about 700 mg. If desired, other components may be included in each pouch.
[0252] The moisture content of an oral product may vary depending on the form in which the composition is provided. In some embodiments described herein, the oral product may be in the form of a wet snuff or snus, and / or may be provided in pouch form. In some embodiments (e.g., in the case of a snus-type product), the moisture content of the composition (before the product is inserted into the user's mouth) may be at least about 20% by weight of the oral product, e.g., at least 30% by weight, e.g., at least 40% by weight, e.g., at least 50% by weight. In some embodiments (e.g., in the case of a snus-type product, e.g., a non-pouch snus product), the moisture content of the composition (before the product is inserted into the user's mouth) may be about 20% to about 70% by weight of the oral product, e.g., about 30% to about 60% by weight, e.g., about 40% to about 55% by weight.
[0253] In some embodiments, the oral product may be a “dry” snus or snuff product. In such embodiments, the moisture content of the oral product may be about 10% by weight or less, for example, about 5% by weight or less. For example, the moisture content may be about 0.1% to about 10% by weight, for example, about 1% to about 5% by weight.
[0254] When in the form of a pouch-type oral product, the oral product typically contains a filler. The filler may preferably be a cellulose material selected from the preferred materials described herein. In some preferred embodiments, the filler is at least MCC or contains MCC. The amount of filler may vary, but is typically at least about 5% to about 95% by weight of the oral product, based on the total weight of the oral product. In some embodiments, the filler (such as a cellulose material like MCC) may be present in the oral product in an amount of about 5% to about 95% by weight, e.g., about 10% to about 90% by weight, e.g., about 15% to about 85% by weight, e.g., about 20% to about 80% by weight, e.g., about 25% to about 75% by weight, e.g., about 30% to about 70% by weight, e.g., about 35% to about 65% by weight, e.g., about 40% to about 60% by weight. In some embodiments, the filler (such as a cellulose material like MCC) may be present in an amount of about 45% to about 55% by weight of the oral product.
[0255] package According to some embodiments described herein, a package containing the oral product described herein is provided. For example, the package may include the oral product in the form of a chew, lozenge, or the like. The package may be in the form of a blister pack, can, or plastic container containing such oral dosage forms.
[0256] According to some embodiments described herein, a package comprising at least one pouch oral product described herein is provided. The pouch product described herein may be packaged in any suitable inner packaging material and / or outer container. Also, for example, U.S. Patent No. 7,014,039 by Henson et al., U.S. Patent No. 7,537,110 by Kutsch et al., U.S. Patent No. 7,584,843 by Kutsch et al., U.S. Patent No. 8,397,945 by Gelardi et al., Design Patent No. D592,956 by Thiellier, Design Patent No. D594,154 by Patel et al., and Design Patent No. D625,178 by Bailey et al., U.S. Patent Publication No. 2008 / 0173317 by Robinson et al., U.S. Patent Publication No. 2009 / 0014343 by Clark et al., U.S. Patent Publication No. 2009 / 0014450 by Bjorkholm, and U.S. Patent No. See the various types of containers for smokeless products described in U.S. Patent Publication No. 2009 / 0250360, U.S. Patent Publication No. 2009 / 0266837 by Gelardi et al., U.S. Patent Publication No. 2009 / 0223989 by Gelardi, U.S. Patent Publication No. 2009 / 0230003 by Thiellier, U.S. Patent Publication No. 2010 / 0084424 by Gelardi, and U.S. Patent Publication No. 2010 / 0133140 by Bailey et al., U.S. Patent Publication No. 2010 / 0264157 by Bailey et al., U.S. Patent Publication No. 2011 / 0168712 by Bailey et al. (these are incorporated herein by reference). For example, the package may be a can or plastic container containing multiple pouches of oral product.
[0257] process The various combinations of components in a composition (e.g., active ingredients and any additives) can vary. Therefore, the overall product containing, for example, powdered composition components may be relatively homogeneous. The components, which may be in liquid or dry solid form, can be mixed in a pre-treatment step before being mixed with any remaining components of the product, or they can simply be mixed with all other liquid or dry components.
[0258] The various components of a product can be brought into contact, combined, or mixed together using any mixing technique or apparatus known in the art. Any mixing method that brings the product components into close contact can be used, such as mixing apparatus featuring an impeller or other agitable structure. Examples of mixing apparatus include casing drums, conditioning cylinders or drums, liquid spraying devices, conical blenders, ribbon blenders, mixers available from Littleford Day, Inc. as FKM130, FKM600, FKM1200, FKM2000 and FKM3000, plow-sear type mixer cylinders, and Hobart mixers. See also, for example, the types of methodologies described in U.S. Patent No. 4,148,325 by Solomon et al., U.S. Patent No. 6,510,855 by Korte et al., and U.S. Patent No. 6,834,654 by Williams et al. (each of which is incorporated herein by reference). In some embodiments, the components forming the product are prepared such that their mixture can be used in a starch molding process to form the product. The forms and methods for formulating the product will be apparent to those skilled in the art. See also, for example, the types of methodologies described in U.S. Patent No. 4,148,325 by Solomon et al., U.S. Patent No. 6,510,855 by Korte et al., and U.S. Patent No. 6,834,654 by Williams et al., U.S. Patent No. 4,725,440 by Ridgway et al., and U.S. Patent No. 6,077,524 by Broder et al. (each of which is incorporated herein by reference).
[0259] Preparation method for chewing products In some embodiments, the product is in chewable form. In such embodiments, the process is (a) The step of contacting at least one binder with at least one sugar, or at least one sugar alcohol, or a combination of at least one sugar and at least one sugar alcohol, and optionally adding water. (b) A step of heating a mixture of a binder, sugar alcohol and / or sugar, and optionally water, (c) A step of adding a combination of active ingredients, (d) solidifying the obtained mixture to obtain an oral chewable product.
[0260] The combination of active ingredients may be as described herein above. The combination of active substances may also be as described below with respect to "further broad embodiments".
[0261] Step (b) of heating the mixture may comprise heating the mixture to a temperature of from about 70°C to about 150°C, for example from about 80°C to about 125°C, such as from about 90°C to about 100°C. Step (b) may optionally comprise heating the mixture until it boils, while optionally agitating the mixture.
[0262] Step (d) preferably comprises a cooling step. In some embodiments, the mixture obtained from step (c) is cooled to solidify and obtain the oral chewable product. For example, after the active ingredient is added in step (c), the resulting mixture may be poured into a mold to remove heat. The mixture may be passively cooled to room temperature. Alternatively, the mixture may be placed in a cold water bath, refrigerator or freezer to lower the temperature. Preferably, cooling is performed at room temperature to solidify the product.
[0263] The combination of active ingredients may be added during the heating step (b). In some embodiments, the combination of active ingredients is added while the mixture of binder, sugar alcohol and / or sugar and optionally water is boiling. Alternatively, the combination of active ingredients may be added after the mixture of binder, sugar alcohol and / or sugar and optionally water has boiled.
[0264] Any additives may be added at any stage in the process described above. In some embodiments, an oxidizing agent is added after the mixture has been removed from the heat, i.e., during step (c) or (d). In some embodiments, a flavoring agent and / or coloring agent is added after the mixture has been removed from the heat, i.e., during step (c) or (d). In some embodiments, a sweetener is added during step (a). Therefore, the sweetener may be included in the mixture heated in step (b).
[0265] For the preparation of chewable products, a binder (e.g., pectin, agar, carrageenan, starch, or a combination thereof) is generally pre-blended with all or part of a sugar alcohol / sugar, sweetener, or a combination thereof. Water is added, and the mixture is heated with stirring until it boils. The remaining sugar alcohol or sweetener is added to the boiling mixture along with the active ingredient, followed by the addition of any buffer. The mixture is cooked to a Brix of about 50-80 degrees. The heat is removed, and any acidifying agents and / or flavorings are added along with any coloring agents, and the mixture is fully combined. The composition is poured into molds for storage at ambient temperature.
[0266] In some embodiments, the composition is poured into a starch mold. A starch tray having a molded shape is prepared and preheated at 60°C for at least 1-2 hours. The starch may be any starch as disclosed above herein. In some embodiments, the starch is cornstarch. In some starch-molded embodiments, the pectin binder is pre-blended with a portion of a sugar alcohol (e.g., isomalt or maltitol). Water is added and the mixture is heated with stirring until it boils. Further sugar alcohols (e.g., maltitol syrup and / or isomalt) are added to the boiling mixture along with the active ingredients. The mixture is cooked to about 78 Brix. The heat is removed and any sweetener (e.g., sucralose or acesulfame K) and flavorings are added along with any colorants and acidifiers (e.g., citric acid solution) to fully combine the mixture. The hot mixture is poured into a starch mold for storage at ambient temperature. The resulting chu is removed from the starch mold, and any excess starch is removed.
[0267] In other embodiments of starch molding, gum powder (e.g., pectin, agar, carrageenan, starch, or a combination thereof) is mixed with water until no lumps remain. Sugar alcohol and / or sugar (e.g., isomalt and / or maltitol syrup) and an optional sweetener (e.g., sucralose) are mixed together, and the mixture is heated to 82-104°C. The gum powder solution is added to the sugar alcohol / sugar and thoroughly mixed. Active ingredients, as well as any color and flavor, are added to the above solution and thoroughly mixed. The mixture is cooked at 93-104°C until the Brix degree reaches 50-80. An aqueous solution of an acidifying agent (e.g., citric acid and / or trisodium citrate dihydrate) is prepared and added to the hot mixture. Then, if necessary, an optional gelling agent (e.g., dicalcium phosphate solution) is added to the mixture. The high-temperature mixture is poured into a prepared starch mold and kept in a 60°C oven overnight, or until proper solidification is achieved. The resulting chu is removed from the starch mold and excess starch is removed. In some embodiments, the chu is coated with, for example, a coating oil or CAPOL 410 (available from Centechem, Inc.). The coating process may be carried out in the same manner as described in detail below with respect to the lozenge product.
[0268] In other embodiments, the composition is poured into a starch-free mold. In other such embodiments, gum powder (e.g., pectin, agar, carrageenan, starch, or a combination thereof) is mixed with water until no lumps remain. Maltitol syrup, sucralose, and optionally isomalt are mixed together, and the mixture is heated to 82-104°C. The gum powder solution is added to the maltitol solution and mixed thoroughly. Active ingredients, as well as any color and flavor, are added, and the mixture is mixed thoroughly. The mixture is cooked at 93-104°C until the Brix degree reaches 50-80. An aqueous solution of citric acid and optionally trisodium citrate dihydrate is prepared and added to the hot mixture to reach a pH of 2.5-4. Then, if necessary, any gelling agent (e.g., dicalcium phosphate solution) is added to the mixture. The hot mixture is poured into a starch-free mold and left at room temperature until proper solidification is achieved.
[0269] The chewing product may be held in a mold (with or without starch) for a predetermined period of time, such as approximately 10 minutes to approximately 24 hours, or even 48 hours, in order to harden and solidify the chewing product.
[0270] According to other aspects of this disclosure, an extrusion process may be used in which the final chew product is extruded as described below with respect to a lozenge extrusion method, rather than using a mold to prepare the chew product.
[0271] Preparation method for lozenge products The forms and methods used to formulate and manufacture the lozenge products described herein may vary. For example, a composition forming a lozenge product may be prepared so that the mixture can be used in a starch molding process for forming a lozenge product. Exemplary lozenge manufacturing processes are described in U.S. Patent No. 4,725,44015 by Ridgway et al. and U.S. Patent No. 6,077,524 by Bolder et al., which are incorporated herein by reference. In some embodiments, a composition for forming a lozenge product may be prepared so that the mixture can be used in a starch-free molding process for forming a lozenge product (e.g., a molding process that does not include starch-based components).
[0272] In some embodiments, the process involves heating the gum, optionally hydrating its components with water, and then stirring the combination of active ingredients into the heated gum components. Generally, the gum may be heated to a temperature in the range of about 60°C to about 80°C for several seconds to several minutes. In some embodiments, the gum may be heated to a temperature of about 71°C before stirring in the combination of active ingredients in order to dissolve the active ingredients in the gum. In some examples, the aqueous mixture is formed in a separate container by mixing one or more additives (e.g., salt, sweetener, humectant, emulsifier, flavoring agent, etc.) with water to form the aqueous mixture.
[0273] The aqueous mixture may then be mixed with heated gum (containing at least one active ingredient added to the gum) to form a mixture in the form of a slurry. In some embodiments, at least one sugar alcohol / sugar component may be added separately to this mixture, or in other embodiments, at least one sugar alcohol may be combined with the gum and active ingredient before being added to the mixture. In some examples, at least one sugar alcohol / sugar may be heated in yet another separate container and added separately to the mixture. For example, in some embodiments, at least one sugar alcohol / sugar (which may optionally contain isomalt / maltitol / erythritol) may be heated to a temperature in the range of about 160°C to about 190°C before being added to the mixture. In some embodiments, at least one sugar alcohol / sugar may be heated to a temperature of at least about 160°C, at least about 170°C, at least about 180°C, or at least about 190°C. In some examples, the heated sugar alcohol / sugar may be cooled to a temperature in the range of about 120°C to about 160°C before being added to the mixture. In some embodiments, for example, the heated sugar alcohol / sugar may be cooled to a temperature of about 160°C or lower, about 150°C or lower, about 140°C or lower, or about 130°C or lower before being added to the mixture.
[0274] In some examples, heated (and optionally cooled) sugar alcohols / sugars may be combined with a mixture (e.g., comprising heated gum, at least one active ingredient, and an aqueous mixture) and stirred using a high-shear mixer or a Hobart mixing bowl equipped with a whisk attachment to provide a lozenge composition, which may also be in the form of a slurry. The lozenge composition is then heated at a high temperature for a certain period of time, for example, to about 40°C to about 80°C, typically to about 71°C for about 1 to about 3 minutes, in order to dissolve any dry components in the lozenge composition. The heating step may be characterized by heating at a temperature of at least about 50°C, at least about 60°C, or at least about 70°C. The lozenge composition may typically have a water content of at least about 40% by weight, based on the total weight of the composition.
[0275] In some embodiments, a lozenge composition in slurry form may be subjected to a degassing step or process before being placed in a mold or subjected to other processing steps in order to reduce or eliminate air bubbles present in the slurry mixture. Air bubbles incorporated into the slurry may affect the final weight of the lozenge product and may lead to a lack of weight uniformity between units of the final product. Therefore, any degassing method and system may be used to remove such air bubbles from the slurry material. For example, to remove air bubbles in a slurry mixture, the slurry may be placed under reduced pressure (i.e., below atmospheric pressure). In some examples, a vacuum degassing process may be used, in which the slurry mixture is placed in a vacuum degasser and the slurry mixture is degassed using reduced pressure. In some examples, the slurry mixture may be under vacuum for about 1 to 10 minutes, typically about 3 to 5 minutes. The degassing step may be observed and adjusted accordingly to controllably remove gaseous components from the slurry mixture.
[0276] The viscosity of the heated and degassed slurry mixture can be measured, for example, using a Brookfield viscometer HA series, SC4 water jacket, 27 / 13R sample chamber, and No. 27 spindle. The lozenge composition may have a viscosity of about 5.7 Pascal seconds (Pa·s) to about 6.2 Pa·s when heated to a temperature of about 38°C, about 4.9 Pa·s to about 5.4 Pa·s when heated to a temperature of about 43°C, and about 4.2 Pa·s to about 4.7 Pa·s when heated to a temperature of about 50°C. In some cases, additional water may be added to the lozenge composition to provide the desired viscosity.
[0277] Once the desired viscosity is achieved, the heated lozenge composition can then be poured into a mold, such as a starch mold. While the process further described herein is intended for forming lozenge products using a starch mold, it should be noted that other types of molds may be used, such as starch-free molds, pectin molds, plastic tray molds, silicone tray molds, metal tray molds, and neoprene tray molds.
[0278] When a starch mold is used, the starch mold may be pre-dried to remove moisture from the mold itself. That is, before containing the slurry or viscous lozenge composition, the starch mold may be subjected to high temperatures to remove moisture from within the starch mold. For example, in some cases, the starch mold may initially have a moisture content of about 10-15% by weight. Such a level of moisture can affect the uniformity of the resulting product. In this regard, certain moisture levels in the starch mold can potentially cause a wrinkle or shrinkage effect on the product, resulting in the final product having a wrinkled or otherwise wrinkled appearance. In such cases, the starch mold may be dried at high temperatures to reduce the moisture content of the starch mold to about 4% to about 10% by weight, preferably about 6% to about 8% by weight, based on the total weight of the starch mold. By performing such a step, the product may, in some cases, have a more uniform appearance. Furthermore, the starch mold can be heated to a high temperature before containing the lozenge composition, so that the starch mold itself becomes hot when it contains the lozenge composition.
[0279] The lozenge composition can remain in the starch mold at high temperatures, such as about 40°C to about 80°C (e.g., at least about 40°C or at least about 50°C), typically about 60°C. The lozenge composition may be held at high temperatures for a predetermined duration, such as about 12 to 48 hours, typically about 24 hours, to allow the lozenge composition to harden and solidify into lozenge form, while bringing the moisture content of the lozenge composition to a desired final moisture level. As described above, in some embodiments, the desired final moisture level of the lozenge product may be in the range of about 5% to about 25% by weight, or about 8% to about 20% by weight, or about 10% to about 15% by weight, based on the total weight of the product unit. In this regard, hardening generally refers to a solidification process in which moisture loss occurs, the viscosity of the composition increases, and chemical and physical changes (e.g., crystallization, crosslinking, gelation, film formation, etc.) begin to occur. The lozenge composition is cooled and then removed from the starch mold. In some cases, the lozenge composition may be refrigerated or cooled below ambient temperature. A blower / shaker device may be used to remove starch residue from the lozenge composition after it has been removed from the starch mold.
[0280] The lozenge product is then post-cured for a time and temperature suitable for achieving equilibrium with the desired moisture content, shape, and form. The time and temperature may vary without departing from the present invention and may partially depend on the desired final properties of the product. In one embodiment, post-curing is carried out at ambient temperature for at least about 20 hours after removal from the mold.
[0281] The lozenge products may be supplied in individual pieces ranging from approximately 0.5 grams to approximately 5 grams, but the disclosure is not limited to such weights.
[0282] The curing time and temperature of the lozenge product can be varied as needed. In this regard, such variables may affect the final visual appearance of the lozenge product. For example, a long curing time and / or low curing temperature may affect the final external configuration or contour of the lozenge product. That is, the rate of drying and / or curing of the product can affect the final properties of the product. In some instances, for example, by lowering the curing temperature and extending the curing time, the lozenge product can have a relatively smooth outer surface. In contrast, curing at a high temperature for a short period of time may result in a roughened or wrinkled appearance of the product.
[0283] According to other aspects of the present disclosure, rather than using a mold to prepare the lozenge product, an extrusion process may be used in which the final lozenge product is extruded. In some examples, the lozenge composition in slurry form is formed into a sheet and dried to a moisture content, for example a moisture content of from about 15 wt% to about 25 wt%, to form a sticky or otherwise pasty material that is in a physically handleable form. The material may then be comminuted, for example using a mixer, or otherwise cut into smaller pieces. The comminuted material may then be extruded through an extrusion device into any desired shape / size, including shapes that may be difficult or impossible to achieve with a mold. In some examples, the extruded product may then be dried to achieve the desired moisture content. A similar type of process is described, for example, in U.S. Pat. No. 3,806,617 to Smylie et al., which is incorporated herein by reference in its entirety. Further, the lozenge composition may be subjected to a co-extrusion process with another composition.
[0284] For example, shapes such as rods and cubes can be formed by first extruding the material through a die having a desired cross-section (e.g., circular or square), and then optionally cutting the extruded material to a desired length. Techniques and apparatus for extruding tobacco material are described in U.S. Patent No. 3,098,492 by Wursburg, U.S. Patent No. 4,874,000 by Tamol et al., U.S. Patent No. 254,880,018 by Graves et al., U.S. Patent No. 4,989,620 by Keritsis et al., U.S. Patent No. 5,072,744 by Luke et al., U.S. Patent No. 5,829,453 by White et al., and U.S. Patent No. 6,182,670 by White et al., each of which is incorporated herein by reference. Suitable exemplary extruders for use include food or gum extruders, or industrial pasta extruders such as the Model TP 200 / 300 available from Emiliomiti, LLC of Italy. In some cases, a single machine may be capable of accomplishing multiple steps of the process described herein, such as the kneader system available from Buss AG.
[0285] The lozenge product can be provided in any suitable predetermined shape or form, most preferably in the form of common shapes such as pills, pellets, tablets, coins, beads, oval, obloid, or cube. The texture of the lozenge product is preferably slightly chewable and dissolvable, having a gentle elasticity or "bounciness" when chewed, which gradually leads to greater malleability during use. According to one embodiment, the lozenge product can preferably remain in the user's mouth for about 10 to 15 minutes until the product is completely dissolved. Preferably, the product leaves no residue in the user's mouth to a substantial degree and does not impart a smooth, waxy, or slimy feeling to the user's mouth.
[0286] According to some embodiments, the lozenge composition may be coated with a coating material after being removed from the starch form and before drying. For example, to provide flow properties, a gloss or anti-stick coating material such as CAPOL 410 (available from Centechem, Inc.) may be applied to the lozenge composition. The coating composition may include oils or waxes, such as sunflower oil and / or carnauba wax.
[0287] The outer coating can also help improve the storage stability of the lozenge products of this disclosure, as well as improve the packaging process by reducing abrasion and dust generation. Devices for providing an outer coating layer to the products of this disclosure include pan coaters and spray coaters, and in particular include coating devices available from Thomas Engineering as CompuLab24, CompuLab36, Accela-Cota48, and Accela-Cota60. Exemplary coatings include film-forming polymers such as cellulosic polymers, any plasticizers, and any flavorings, colorants, salts, sweeteners, or other additives of the kinds described herein. The coating compositions are typically aqueous in nature and can be applied using any pellet or tablet coating techniques known in the art, such as pan coating. Typical film-forming polymers include cellulose polymers such as methylcellulose, hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose, and carboxymethylcellulose. Typical plasticizers include aqueous solutions or emulsions of glyceryl monostearate and triethyl citrate.
[0288] In one embodiment, the coating composition comprises up to about 75% by weight of a film-forming polymer solution (e.g., about 40 to about 70% by weight based on the total weight of the coating formulation), up to about 5% by weight of a plasticizer (e.g., about 0.5% to about 2% by weight), up to about 5% by weight of a sweetener (e.g., about 0.5% to about 2% by weight), up to about 10% by weight of one or more colorants (e.g., about 1% to about 5% by weight), up to about 5% by weight of one or more flavorings (e.g., about 0.5% to about 3% by weight), up to about 2% by weight of a salt such as NaCl (e.g., about 0.1% to about 15% by weight), and the remainder water. Exemplary coating compositions and methods of application are described in U.S. Patent Application No. 12 / 876,785 by Hunt et al., filed on 7 September 2010, which is incorporated herein by reference.
[0289] While the above description focuses on a uniform composition throughout each product unit, products can also be formed from multiple different formulations having different properties within the same product unit. For example, two different compositions can be poured into a single mold to produce a layered product. Furthermore, two different compositions can be co-extruded to form a product having different properties across its cross-section. Such a process can be used to provide a product having two different compositions characterized by different dissolution rates, such that a first portion of the product dissolves at a first rate (e.g., a faster rate) and a second portion dissolves at a second, slower rate.
[0290] Method for preparing tablet products In some embodiments, the product is in the form of compressed pellets or tablets. In one embodiment, the process for producing the pellets or tablets first involves mixing a bulk filler (e.g., EMDEX®) with the active ingredient. Then, the remaining composition ingredients (e.g., sugar alcohols and any other desired ingredients, e.g., binders, colorants, sweeteners, flavorings, etc.) are added. Optionally, a colorant may be added to one of the composition ingredients in a separate step before being mixed with the remaining ingredients of the composition. Mixing of the composition can be achieved using any mixing device. The final composition is then compressed into the form of pellets or tablets using conventional tableting techniques and optionally coated. Compressed composition pellets can be produced by compressing a composition containing any relevant formulation ingredients into pellet form and optionally coating each pellet with an overcoat material. Exemplary compression devices, such as compression presses, are available from Vector Corporation as Colton 2216 and Colton 2247, and from Fette Compacting as 1200i, 2200i, 3200, 2090, 3090, and 4090. Devices for providing an outer coating layer to the compressed pelletized composition are available from Thomas Engineering as CompuLab 24, CompuLab 36, Accela-Cota 48, and Accela-Cota 60.
[0291] If present, the coating typically comprises a film-forming polymer such as a cellulosic polymer, any plasticizer, and any flavorings, colorants, salts, sweeteners, or other additives of the kind described herein. The coating composition is usually aqueous in nature and can be applied using any pellet or tablet coating technique known in the art, such as bread coating. Typical film-forming polymers include cellulose polymers such as methylcellulose, hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose, and carboxymethylcellulose. Typical plasticizers include aqueous solutions or emulsions of glyceryl monostearate and triethyl citrate. Additional potential coatings include food-grade shellac, waxes such as carnauba wax, and combinations thereof.
[0292] Method for preparing lozenge products The forms and methods used to formulate and manufacture the lozenge products described herein may vary. For example, the compositions may be prepared by any method commonly used for the preparation of hard confectionery. Exemplary methods for the preparation of hard confectionery can be found, for example, in the LFRA Ingredients Handbook, Sweeteners, Janet M. Dalzell, Ed., Leatherhead Food RA (Dec. 1996), pp. 21-44, which is incorporated herein by reference.
[0293] Typically, a first mixture of components is prepared. The composition of the first mixture of components can vary, but it typically contains a sugar substitute and may contain various additional substances (e.g., sugar alcohol syrup, NaCl, preservatives, further sweeteners, water, and / or flavorings). In certain embodiments, the mixture contains a sugar substitute, salt, and vanillin. In other embodiments, the first mixture contains a sugar substitute and sugar alcohol syrup. Typically, the first mixture of components does not contain an active ingredient, but in some embodiments, an active ingredient may be incorporated into the first mixture of components.
[0294] The first mixture of components is heated until melted, and then the mixture is heated to or past the hard crack stage. In confectionery, the hard crack stage is defined as the temperature at which a thread of the heated mixture (obtained by pulling a sample of cooled syrup between the thumb and index finger) becomes brittle, or the temperature at which cracks appear when attempting to mold the syrup. According to this method, the temperature at which the hard crack stage is achieved may vary depending on the specific composition of the product mixture, but is generally about 145°C to about 170°C. Typically, the mixture is not heated above about 171°C, the temperature at which caramelization begins. In the process of this disclosure, the mixture is typically heated above the hard crack stage temperature and then cooled. Heating may be carried out under atmospheric pressure or vacuum. Typically, the method of the present invention is carried out under atmospheric pressure.
[0295] In one exemplary embodiment, the first mixture of components contains a high proportion of isomalt, and the mixture is heated to approximately 143°C. Once all components have dissolved, the temperature is raised beyond the hard cracking stage (e.g., to approximately 166°C). The mixture is heated to this temperature and then removed from the heating and allowed to cool.
[0296] In certain embodiments, the above-mentioned active ingredients and optionally additional ingredients (e.g., additional sweeteners, fillers, flavorings, and water) are combined separately in a second mixture. The second mixture is typically added to the first mixture of ingredients after it has been removed from heat. In some embodiments, the addition of the second mixture may only occur after the heated first mixture of ingredients has cooled to a predetermined temperature (e.g., to about 132°C in certain embodiments). In certain embodiments, one or more flavorings are added to the second mixture immediately before the mixture is added to the first heated mixture of ingredients. Certain flavorings are volatile and are therefore preferably added after the mixture has cooled somewhat. The combined mixture is then formed into a desired shape. In certain embodiments, the mixture is either poured directly into a mold, formed into a desired shape (e.g., rolled or pressed), or extruded. If desired, the mixture may be extruded or injection molded. In certain embodiments, the mixture is formed or extruded into a mold of a desired shape within a sealed system, which may require a reduction in temperature and can limit the evaporation of certain mixture components. For example, such a system may limit the evaporation of volatile components, including, but is not limited to, flavorings. Other methods for producing lozenges are also intended to be incorporated herein.
[0297] Typical conditions related to the manufacture of food-grade lozenge products as described herein include control of heat and temperature (i.e., the degree of heat to which various components are exposed during manufacture and the temperature of the manufacturing environment), moisture content (e.g., the degree of moisture present in individual components and in the final composition), humidity in the manufacturing environment, atmosphere control (e.g., nitrogen atmosphere), airflow experienced by various raw materials during the manufacturing process, and other similar factors. Furthermore, various process steps involved in product manufacturing may include the selection of specific solvents and processing aids, the use of heat and radiation, refrigeration and cryogenic conditions, and component mixing rates. Manufacturing conditions can also be controlled by the selection of various component forms (e.g., solid, liquid, or gas), particle size or crystalline properties of components in solid form, and concentration of components in liquid form. Components can be processed into desired compositions by techniques such as extrusion, compression, and spraying.
[0298] In certain embodiments, the lozenge product may be transparent or translucent. As used herein, “translucent” or “translucent” refers to a material that allows a certain level of light to pass through diffusely. In certain embodiments, the lozenge product of this disclosure may have a degree of transparency such that the material can be classified as exhibiting “transparency” or “translucency,” which is defined as a material that allows light to pass through freely without significant diffusion. The transparency of the lozenge product is such that it has a degree of translucency, as opposed to opaque (a material that does not allow light to pass through).
[0299] Transparency / transparency can be determined by any means commonly used in the art, but is generally measured by spectrophotometric light transmission over a range of wavelengths (e.g., about 400–700 nm). Alternatively, the cloudiness (light scattering) and color (light absorption) of a product can be quantified, respectively, using optical methods such as turbidity measurement (or turbidimetry) and colorimetry. Transparency can also be confirmed by visual inspection, simply by lifting the product to a light source and determining whether light passes through the material (e.g., extract) or product in a diffuse manner.
[0300] Method for preparing molten products In some embodiments, the product is in a molten form. For the preparation of a molten product, the lipids are typically heated to a temperature slightly above their melting point so that the lipids liquefy. Optionally, active ingredients, flavorings, and / or lecithin may be added to the liquefied lipids at this stage. All or part of the liquefied lipids are then blended with the dry blend and mixed until the product reaches a desired level of homogeneity or until desired texture characteristics are achieved. The mixture is ground to a particle size of less than about 20 micrometers (e.g., in a dry roll mill). The ground isomaltopalm oil is combined with any remaining lipids, dry ingredients, and flavorings. The base material is generally heated to a fluid consistency.
[0301] In some embodiments, a sugar alcohol (e.g., isomalt) is added to the mixer bowl, along with salt and an emulsifier, and a portion of the total lipids (e.g., molten palm oil).
[0302] Additional lipids are added while mixing until a sticky mass is formed. The aggregated mixture is partially transferred to a 3-roll mill and processed to a particle size of less than 50 micrometers or about 20 micrometers. The purified mixture is transferred to a mixer bowl and the remaining lipids are added while mixing. The mixture is heated as needed to maintain fluid consistency.
[0303] Sweeteners, flavorings, and active ingredients are added while mixing. Mixing continues until a homogeneous composition is obtained. The mixture is allowed to stand for a certain period, for example, about 10 to 15 minutes. The composition can be divided into separate parts, for example, by pouring the composition into a sheet-like structure, cooling it, and then cutting the structure into individual parts, or by pouring the composition into a mold and allowing it to cool. The mold may be a starch mold or a starch-free mold. In certain embodiments, the mold is starch-free.
[0304] To cool and solidify the molten composition, it may be held in a mold (with or without starch) for a predetermined period of time, for example, about 1 to 15 minutes. Optionally, the mold containing the molten product may be cooled by refrigeration to accelerate solidification.
[0305] According to other aspects of the present disclosure, an extrusion process may be used in which the final molten product is extruded as described above with respect to the lozenge extrusion method, rather than using a mold to prepare the molten product.
[0306] Method for preparing pouch oral products If the product is in the form of a pouched oral product, the process is: (a) The step of combining the active ingredients, (b) The step of bringing a combination of an active ingredient and at least one filler into contact to obtain an oral product may include:
[0307] The combination of active ingredients may be as described above herein. The combination of active substances may also be as described below with respect to “further broader embodiments”.
[0308] In some embodiments, step (b) includes mixing at least one filler with a combination of active ingredients. In some embodiments, the combination of active ingredients is in solid form (e.g., in powder form). The combination of active ingredients may be mixed directly with the filler to obtain an oral product. In some embodiments, the combination of active ingredients may be dissolved in a hydrophilic solvent (e.g., water and / or alcohol) before contact with the filler. For example, the combination of active ingredients may be dissolved in water or alcohol (e.g., ethanol or propylene glycol) before being mixed with the filler. In such embodiments, this process may include a step of drying the product to remove the solvent. For example, the product may be dried by heating, freeze-drying, spray-drying, or simply by leaving the product at room temperature for a specific period of time. Preferably, the drying step includes leaving the product at room temperature for 1 to 48 hours to remove the solvent.
[0309] The process may then further include the step of packaging the oral product using pouch material as described above in this specification.
[0310] use According to some embodiments described herein, the use of a combination of active ingredients for increasing alertness and / or energy levels in humans or animals is provided, wherein the combination of active ingredients comprises (i) caffeine, (ii) a combination of B vitamins including vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) taurine.
[0311] In some embodiments, use may include increasing or enhancing the energy levels of the subject to which the combination of active ingredients is administered. Use may include enhancing the subject's alertness. Additionally or alternatively, use may include increasing the subject's concentration and / or cognitive abilities.
[0312] In some embodiments, the combination of active ingredients is as defined above herein. In such embodiments, the combination may further include any of the additional active ingredients described above herein. For example, the combination of active ingredients may further include vitamin C and / or ginseng. The combination of active ingredients may, in particular, further include ginseng.
[0313] Alternatively, the combination of active ingredients may be as described below in any of the “further broader embodiments.” For example, the combination of active ingredients may include (i) caffeine, (ii) ginseng, and (iii) taurine. Alternatively or additionally, the combination of active ingredients may include (i) caffeine, (ii) at least one B vitamin selected from the group consisting of vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12, and (iii) ginseng. Alternatively or additionally, the combination of active ingredients may include (i) caffeine, (ii) at least one B vitamin selected from the group consisting of vitamin B2, vitamin B3, vitamin B6, vitamin B9, and vitamin B12, (iii) taurine, and (iv) vitamin C.
[0314] Alternatively or additionally, the combination of active ingredients may include (i) caffeine and (ii) taurine, where caffeine and taurine are present in a weight ratio of approximately 1:1, and the combination of active ingredients may further include (iii) at least one B vitamin selected from the group consisting of vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, or (iv) ginseng.
[0315] The combination of active ingredients may provide an improved effect compared to previously known products, increasing the consumer's mental attention. The inventors have found that specific combinations of the active ingredients of the present invention can improve alertness, increase physical and / or mental energy levels, and enhance cognitive effects such as reduced reaction time and fatigue during cognitive tasks.
[0316] Further broader aspects According to some embodiments described herein, (i) Caffeine (ii) Ginseng, and (iii) A combination of active ingredients including taurine, At least one binder, and A chewable solid oral product is provided, comprising a sugar alcohol, or a sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar.
[0317] With respect to the first embodiment, the amounts of caffeine, taurine, and ginseng (and all other active ingredients and / or additives) described herein are equally applicable to such embodiments comprising (i) caffeine, (ii) ginseng, and (iii) taurine, and are not repeated here for brevity. All amounts and combinations described herein are equally applicable to this embodiment in which the inclusion of a combination of B vitamins is not essential.
[0318] In some embodiments, the combination of active ingredients includes (i) about 0.1% to about 5% by weight of caffeine in the oral product, (ii) about 0.01% to about 1% by weight of ginseng in the oral product, and (iii) about 0.01% to about 5% by weight of taurine in the oral product.
[0319] In some embodiments, the oral product is (i) Caffeine, (ii) Ginseng, and (iii) Taurine are included in the combination of active ingredients, Here, the weight ratio of caffeine to taurine is approximately 5:1 to approximately 1:1. The weight ratio of caffeine to ginseng is approximately 50:1 to 30:1. The weight ratio of taurine to ginseng is approximately 20:1 to 10:1.
[0320] Preferably, the weight ratio of caffeine to taurine is approximately 3:1.
[0321] In some embodiments, the oral product is (i) Caffeine, (ii) Ginseng, and (iii) Taurine are included in the combination of active ingredients, Here, the weight ratio of caffeine to taurine is approximately 5:1 to approximately 1:1. The weight ratio of caffeine to ginseng is approximately 60:1 to 30:1. The weight ratio of taurine to ginseng is approximately 25:1 to 10:1.
[0322] Preferably, the weight ratio of caffeine to taurine is approximately 4:1 to approximately 1:1.
[0323] In some embodiments, the oral product is (i) Caffeine, (ii) Ginseng, (iii) Taurine, and a combination of other active ingredients Here, the weight ratio of caffeine to taurine is approximately 2:1 to 4:1.
[0324] In some embodiments, the oral product is (i) Caffeine, (ii) Ginseng, (iii) Taurine, and a combination of other active ingredients Here, the weight ratio of caffeine to taurine is approximately 3:1.
[0325] In some embodiments, the oral product is (i) Approximately 1 mg to 250 mg of caffeine, (ii) Ginseng in an amount of approximately 0.01 mg to approximately 5 mg, (iii) An oral chewable product containing approximately 1 mg to 200 mg of taurine.
[0326] In some embodiments, the oral product is (i) Approximately 10 mg to 100 mg of caffeine, (ii) Ginseng in an amount of approximately 0.01 mg to approximately 5 mg, (iii) An oral chewable product containing approximately 5 mg to 50 mg of taurine.
[0327] In any of the embodiments described above, the oral product may further contain additional active ingredients as described herein with respect to the first embodiment. In particular, the oral product may further contain at least one B vitamin and / or vitamin C. The range and combinations of these additional active ingredients described herein apply equally to these embodiments. In some preferred embodiments, the oral product may further contain at least one B vitamin selected from the group consisting of vitamins B2, B3, B6, B9, B12 and combinations thereof. In some embodiments, the oral product may contain at least a combination of vitamins B6, B9, and B12. The preferred range of amounts of these B vitamins is as described above.
[0328] The processes and uses described herein may also apply equally to the embodiments described above, in which the combination of active ingredients comprises (i) caffeine, (ii) ginseng, and (iii) taurine.
[0329] According to some embodiments described herein, (i) Caffeine, (ii) at least one B vitamin selected from the group consisting of vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) A combination of active ingredients including ginseng, At least one binder, and A chewable solid oral product is provided, comprising a sugar alcohol, or a sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar.
[0330] According to some embodiments described herein, (i) Caffeine, (ii) Ginseng, and (iii) A combination of active ingredients including taurine, At least one binder, and A chewable solid oral product is provided, comprising a sugar alcohol, or a sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar.
[0331] According to some embodiments described herein, (i) Caffeine, (ii) at least one B vitamin selected from the group consisting of vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, (iii) Taurine, (iv) A combination of active ingredients including vitamin C, At least one binder, and A chewable solid oral product is provided, comprising a sugar alcohol, or a sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar.
[0332] With respect to the first embodiment, the amounts of all active ingredients and / or additives described herein are equally applicable to such embodiments and will not be repeated here for brevity.
[0333] The processes and uses described herein can also be applied to the embodiments described above.
[0334] Examples Aspects of the present invention are more fully illustrated by the following embodiments, which are described to illustrate specific aspects of the invention and should not be construed as limitations thereof.
[0335] Example 1 - Oral chewable product prepared in a starch-type medium Products according to embodiments of the present disclosure in chewable form are prepared from a composition containing a mixture of fillers, a combination of taurine and caffeine, a combination of vitamins B2, B3, B6, B9, B12, ginseng and vitamin C (as active ingredients), and additional ingredients disclosed herein (sucralose as a sweetener, flavoring agents, water, coloring agents, pectin and citric acid as binders). The fillers include a combination of isomalt syrup and maltitol syrup.
[0336] The pectin binder is pre-blended with a portion of the isomalt. Water is added, and the mixture is heated while stirring until it boils. Maltitol syrup and any remaining isomalt are added to the boiling mixture along with the active ingredients (e.g., taurine, ginseng, caffeine, B vitamins, and vitamin C). The mixture is cooked to 78 Brix. The heat is removed, and the sweetener (e.g., sucralose), coloring agent, and flavoring agent are added along with citric acid, and the mixture is thoroughly combined. The composition is then poured into starch molds to be stored at ambient temperature. Each chu weighs 2600 mg.
[0337] Example 2 - Oral chewable product in a starch-free form Products according to embodiments of the present disclosure in chewable form are prepared from a composition containing a filler, an active ingredient (see Example 1), and a mixture of additional ingredients disclosed herein (sucralose as a sweetener, a flavoring agent, water, a coloring agent, pectin as a binder, and citric acid). The filler includes a combination of isomalt and maltitol syrup.
[0338] Mix the pectin with water until there are no lumps. Mix the maltitol syrup, isomalt, and sucralose together and heat the mixture to 82-104°C. Add the pectin solution to the maltitol / isomalt solution and mix thoroughly. Add the active ingredients, colorants, and flavorings and mix thoroughly. Cook the mixture at 93-104°C until the Brix reaches 50-80. Prepare an aqueous citric acid solution and add it to the hot mixture to reach a pH of 2.5-4. Pour the hot mixture into a starch-free mold and leave at room temperature until proper solidification is achieved.
[0339] Example 3 - Oral lozenge product An oral product in the form of a lozenge, configured for oral use, is provided in the following manner:
[0340] Prepare an aqueous mixture. The aqueous mixture is formed by mixing water, salt, sweetener (sucralose), humectant (glycerin), and flavoring agent. Next, heat the gum (gum arabic) solution to a temperature of approximately 71°C and stir the combination of active ingredients (for example, taurine, caffeine, a combination of vitamins B2, B3, B6, B9, and B12, ginseng, and optionally vitamin C) in the heated gum mixture.
[0341] Next, the heated gum (containing at least one active ingredient) is added to the aqueous composition to form a mixture. Then, at least one sugar alcohol (e.g., isomalt, maltitol, and erythritol) is heated to a temperature of about 175°C and then cooled to a temperature of about 150°C. The cooled sugar alcohol is then added to the mixture and stirred in a Hobart mixing bowl to form a lozenge composition, which is then allowed to cool.
[0342] The lozenge composition is heated to approximately 71°C and then poured into a starch mold. The lozenge composition remains in the starch mold at approximately 60°C for approximately 24 hours. The lozenge composition is cooled and then removed from the starch mold. The oral product is then cured at ambient room temperature for approximately 24 hours to obtain a lozenge product prepared for oral use.
[0343] Example 4 - Oral melt Compositions according to embodiments of the present disclosure in a molten form are prepared from compositions containing as active ingredients a filler (e.g., isomalt), a lipid (e.g., palm oil), a mixture of taurine and caffeine, a combination of vitamins B2, B3, B6, B9 and B12, ginseng, and optionally vitamin C, and additional ingredients disclosed herein (salts, sweeteners, flavorings).
[0344] A portion of the palm oil is melted in a mixer and mixed with isomalt. The mixture is transferred to a dry roll mill and ground until the particle size is less than approximately 20 micrometers. In the mixer, the ground isomalt-palm oil is combined with the remaining palm oil. The mixture is heated to a fluid consistency. Sunflower oil, dry ingredients, and flavorings are added. The isomalt-palm oil mixture is transferred to a heated pouring funnel. An appropriate weight of sample is poured into a starch-free mold. If necessary, the mold is placed on a vibrator to ensure uniform filling. The product is allowed to cool and solidify, then removed from the mold. The weight of each molten product is 1300 mg.
[0345] Example 5 - Chewable Dosage Form Prepare an oral product in the form of a chewer containing the following ingredients: water Vitamin B2 - 0.88 mg Vitamin B3 (as niacinamide) - 4 mg Vitamin B6 - 0.76 mg Vitamin B9 (as folic acid) - 6.66 μg Vitamin B12 - 0.006 mg Caffeine (green tea extract) - 40mg Taurine Vitamin C - 77mg Ginseng root extract Acidifying agents Sucralose pectin Isomalt Maltitol syrup Flavoring
[0346] The total blend of caffeine, taurine, and ginseng is present in an amount of 51 mg. The oral product has a mass of 4 g per serving.
[0347] Prepare the oral product as described in Example 2.
[0348] Example 6 - Results of Consumer Tests A study was conducted to compare the product prepared in Example 5 with a placebo (chew containing no active ingredients) and a commercially available chew. The commercially available chew (OLLY® Daily Energy) contained 150 mg of vitamin B12, 15 mg of coenzyme Q10, and 100 mg of goji berry per chew.
[0349] Five treatment groups administered to subjects from different groups. i) Three placebo tubes, ii) Two tubes from Example 5, and a placebo tube (a total of three tubes), iii) Three tubes of Example 5, iv) The four tubes of Example 5, or v) A blinded study was conducted using two commercially available energy chutes and one placebo chute (a total of three chutes).
[0350] Participants were evaluated by performing cognitively demanding tasks in the period immediately following ingestion, and the following factors were assessed over a period of 90 or 110 minutes after ingestion. These factors were part of the Cognitive Needs Battery (CDB) or self-reported psychological assessments.
[0351] The cognitive battery, administered using COMPASS (a computerized mental performance assessment system), included rapid visual information processing (RVIP), sequential subtraction by 7, numerical working memory (NWM), and Corsi blocks. Each of these tasks assesses different aspects of cognitive function, such as working memory, executive function, and sustained attention.
[0352] Self-reported measurements using CompuSense (web-based software for consumer and sensory testing provided by Compusense Inc.) included the Mood Profile Scale (POMS), Social Activity Measure (SAM), Visual Analog Scales (VAS: Mental Attention, Distractibility, Arousal, Boredom, Physical Tremor, Relaxation, Stimulation, and Concentration), and the Mood Attribute Check (CATA). All are validated self-report questionnaires used to measure mood and emotion.
[0353] The Zung scale was used to screen for anxiety and depression, respectively, before the test. This is a validated self-report questionnaire.
[0354] The Quality of Life Scale (QOLS) was used to evaluate the research group and facilitate bridging between different research groups. In this case, too, it was a validated self-report questionnaire used to measure anxiety in adults.
[0355] Interviews conducted at the end of the study were used for qualitative evaluation.
[0356] The following factors were evaluated. Cognitive Accuracy – Consumers were tested using Rapid Visual Information Processing (RVIP), the most demanding test within the cognitive battery. For RVIP, the results showed that the product in Example 5 was significantly superior to both placebo and the commercial product at both doses, maintaining cognitive (RVIP) accuracy for up to 90 minutes after ingestion during a difficult task. This is shown in Figure 1, where corresponding letters indicate significant changes from placebo and the commercial product.
[0357] Mental arithmetic was evaluated by measuring and scoring consecutive subtraction (by 7 and by 3). For example, as shown in Figure 2, the oral product of Example 5 generally outperformed the placebo and commercial product, demonstrating superior cognitive ability in consecutive subtraction (by 7) over the time course of the required battery (40–90 minutes after ingestion). This was particularly true between 60–80 minutes. Significant changes were shown at the two dose levels, with corresponding letters indicating significant changes from the placebo and commercial product.
[0358] Overall cognitive accuracy—RVIP, numerical working memory (NWM), and a composite score of sequential subtractions of 7 and 3 after ingestion—provides a measure of overall cognitive accuracy. As shown in Figure 3, the oral product of Example 5 improved overall cognitive accuracy compared to placebo and the commercial product. Significant changes were shown compared to placebo at two different doses (indicated by corresponding letter notation).
[0359] Arousal – Perceived effects were measured using a Visual Analog Scale (VAS), ranging from "least aroused" to "most aroused." As shown in Figure 4, perceived arousal for the oral product in Example 5 was significantly higher than that of the placebo and the commercial product, and was maintained over a period of 50–110 minutes after ingestion (corresponding letters indicate significant changes from the placebo and commercial product).
[0360] Physical Energy – Perceived effects were measured using a Visual Analog Scale (VAS), ranging from "least physically energetic" to "most physically energetic." As shown in Figure 5, perceived physical energy for the oral product in Example 5 was significantly higher than that of the placebo and commercial product, and this was maintained over a period of 50–110 minutes after ingestion (corresponding letters indicate significant changes from placebo and commercial product). A particularly significant increase in energy was observed in the three tubes of Example 5.
[0361] Fatigue - Workers were subjected to cognitively demanding tasks designed to induce fatigue. Perceived effects were measured using a Visual Analog Scale (VAS), ranging from "least fatigued" to "most fatigued." As shown in Figure 6, perceived fatigue for the oral product in Example 5 was significantly reduced compared to placebo and the commercial product and was maintained over a period of 50–90 minutes after ingestion (corresponding letters indicate significant changes from placebo and the commercial product).
[0362] Stimulation – Perceived effects were measured using a Visual Analog Scale (VAS), ranging from "least stimulated" to "most stimulated." As shown in Figure 7, the perceived stimulation for the oral product in Example 5 was significantly greater than that for the placebo (as indicated by the corresponding lettering), and in the three chews of Example 5, it tended to be greater than that for the commercial product. The increase relative to placebo was maintained for 30–110 minutes.
[0363] Physical Tremors – Physical tremors may be perceived as beneficial in preparing for physical activity. Perceived effects were measured using a Visual Analog Scale (VAS), ranging from "minimum physical tremor" to "maximum physical tremor." As shown in Figure 8, perceived physical tremors for the oral product in Example 5 were significantly higher than those for placebo and commercial products (corresponding letters indicate significant changes from placebo and commercial products) and were maintained over a period of 30–110 minutes after ingestion. Although perceived physical tremors increased, the time course suggests smooth / sustained activation by the Chew in Example 5.
[0364] Overall mood maintenance was assessed using the Mood Profile Scale (POMS). The cognitively demanding task performed was designed to be difficult, boring, and tiring, and was expected to cause mood deterioration over time. This is shown by the placebo results in Figure 9. However, the Chew in Example 5 mitigated / modulated this mood disorder during the performance of the difficult task. The Chew in Example 5 was significantly better than placebo in attenuating negative mood changes (indicated by the corresponding letter, i.e., "A"). The Chew in Example 5 also showed improvement over the commercial product in the 30–75 minute time frame after ingestion.
[0365] The endpoints and methods can be summarized as follows:
[0366] [Table 1]
[0367] The study participants (n=17, between groups) were aged 18–40 years and were considered healthy adults. Inclusion criteria included being non-smokers, nicotine non-users, self-reported good physical / mental health (using Zung and QOLS scales), self-reported positive stress lifestyles, and a positive attitude towards health and well-being products. Exclusion criteria included use of prescription and recreational drugs, CBD use, caffeine intake of less than 120 mg or more than 400 mg per day, arrhythmia or other cardiac conditions, pregnancy or lactation, self-reported moderate / severe anxiety and depression (using Zung and QOLS scales), self-reported sleep disturbances, self-reported gastrointestinal problems, and arithmetic disorders. Participants acclimatized to the study one week prior to administration, refrained from physical activity and caffeine 10 hours prior to the study, and refrained from any food or drink up to one hour prior to the study.
[0368] Cognitive battery tests were performed before administration of one of the products (NWM, Corsi block, RVIP, consecutive subtraction of 7, consecutive subtraction of 3). Similarly, mood battery tests (COMPASS POMS and VAS) were performed before administration of one of the products. These tests yielded baseline results. Each participant then administered the oral product as specified according to their assigned treatment arm, and these products were tested in a double-blind approach. Approximately 30 minutes after administration, participants underwent the same cognitive battery tests as baseline. These tests were then repeated several times over periods of up to 90 or 110 minutes after administration. During each test period, a time-occupying documentary was shown.
[0369] As explained above, the research results are shown in Figures 1 to 9.
[0370] The results showed how each of the two and three chew doses of the present invention improved performance on cognitive tasks, with both the two and three chew doses performing similarly. The two and three chew doses of the present invention also showed improved performance on mood scales, generally helping participants feel more focused and alert / attentional, while mitigating negative mood swings during challenging tasks. Quantitative measurements were confirmed by qualitative post-study interviews.
[0371] Example 7 - Chewable Dosage Form Prepare an oral product in the form of a chewer containing the following ingredients: water Vitamin B2 - 0.8 mg Vitamin B3 (as niacinamide) - 4 mg Vitamin B6 - 0.6 mg Vitamin B9 (as folic acid) - 0.6 mg Vitamin B12 - 0.5 mg Caffeine (green tea extract) - 30mg Taurine - 10mg Vitamin C Acidifying agents Sucralose pectin Isomalt Maltitol syrup Flavoring
[0372] The oral product has a mass of 4g per serving.
[0373] Prepare the oral product as described in Example 2.
[0374] The various embodiments described herein are presented solely to aid in understanding and teaching the claimed features. These embodiments are provided only as representative examples of embodiments and are not exhaustive and / or exclusive. The advantages, embodiments, examples, functions, features, structures, and / or other aspects described herein should not be considered limitations to the scope of the invention as defined by the claims or to equivalents of the claims, and it should be understood that other embodiments may be used and modified without departing from the scope of the claimed invention. Various embodiments of the invention may suitably include, consist of, or essentially consist of, appropriate combinations of disclosed elements, components, features, parts, steps, means, etc., other than those specifically described herein. Furthermore, this disclosure may include other inventions that are not currently claimed but may be claimed in the future.
[0375] Clause 1. (i) Caffeine, (ii) A combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) Taurine, A combination of active ingredients including At least one binder, and A solid oral product comprising a sugar alcohol, or a sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar. 2. The solid oral product described in Clause 1, wherein the total amount of B vitamins contained in the combination is approximately 0.1% to approximately 5% by weight of the oral product. 3. A solid oral product as described in Clauses 1-2, wherein caffeine is present in an amount of approximately 0.1% to approximately 5% by weight of the oral product. 4. A solid oral product as described in any one of clauses 1 to 3, wherein taurine is present in an amount of approximately 0.01% to approximately 5% by weight of the oral product. 5. A solid oral product as described in any one of clauses 1 to 4, containing caffeine and taurine in a weight ratio of approximately 5:1 to approximately 1:1. 6. A solid oral product as described in any one of clauses 1 to 5, containing caffeine and taurine in a weight ratio of approximately 3:1. 7. A solid oral product as described in any one of clauses 1 to 6, wherein the total amount of caffeine and B vitamins is present in a weight ratio of approximately 1:1 to approximately 10:1. 8. A solid oral product as described in any one of clauses 1 to 7, wherein the total amount of taurine and B vitamins is present in a weight ratio of approximately 5:1 to approximately 1:1. 9. A solid oral product according to any one of clauses 1 to 8, wherein the combination of active ingredients further contains (iv) vitamin C, and in some cases vitamin C is present in an amount of about 0.1% to about 5% by weight of the oral product. 10. A solid oral product as described in Clause 9, wherein the total amount of vitamin C and B vitamins is present in a weight ratio of approximately 1:1 to approximately 10:1. 11. A solid oral product according to any one of clauses 1 to 10, wherein the combination of active ingredients further comprises (v) ginseng, and ginseng may be present in an amount of about 0.001% to about 0.1% by weight of the oral product. 12. A solid oral product according to any one of the clauses 1 to 11, wherein the combination of active ingredients further comprises (vi) vitamin D. 13. A solid oral product as described in any one of Clauses 1 to 12, wherein the oral product contains a combination of active ingredients in an amount of approximately 0.5% to approximately 10% by weight of the oral product. 14. A solid oral product according to any one of the clauses 1 to 13, further comprising one or more additives selected from the group consisting of flavoring agents, sweeteners, acidifying agents, fillers, humectants, preservatives, and mixtures thereof. 15. A solid oral product as described in Clause 14, wherein the oral product contains an acidifying agent. 16. A solid oral product according to any one of clauses 1 to 15, wherein the oral product further contains zinc or zinc gluconate, and optionally the zinc or zinc gluconate is present in an amount of about 0.001% to about 5% by weight of the oral product. 17. A solid oral product according to any one of the clauses 1 to 16, wherein the oral product contains at least one sugar alcohol. 18. A solid oral product according to any one of the clauses 1 to 17, wherein at least one sugar alcohol is selected from the group consisting of erythritol, arabitol, ribitol, isomalt, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, sorbitol, and combinations thereof, and optionally, at least one sugar alcohol is maltitol or contains maltitol. 19. A solid oral product according to any one of the clauses 1 to 18, wherein at least one sugar alcohol is present in an amount of about 40% to about 99% by weight of the oral product. 20. A solid oral product according to any one of the clauses 1 to 19, wherein the oral product comprises at least one sugar alcohol, including a combination of isomalt and maltitol, and optionally, at least one sugar alcohol is present in an amount of about 50% to about 99% by weight of the oral product. 21. A solid oral product according to any one of the clauses 1 to 20, wherein the oral product comprises a combination of at least one sugar alcohol and a sugar, and optionally, at least one sugar alcohol is or contains maltitol. 22. A solid oral product according to any one of the clauses 1 to 21, wherein at least one binder is selected from the group consisting of cellulose derivatives, povidone, sodium alginate, starch-based binders, pectin, carrageenan, pullulan, zein, and combinations thereof, and optionally, at least one binder is pectin or contains pectin. 23. A solid oral product according to any one of the clauses 1 to 22, wherein at least one binder is present in an amount of about 0.001% to about 5% by weight of the oral product. 24. A solid oral product as described in any one of Clauses 1 to 23, wherein the oral product is in the form of a soluble tube. twenty five. (a) The step of contacting at least one binder with at least one sugar, or at least one sugar alcohol, or a combination of at least one sugar and at least one sugar alcohol, and optionally adding water. (b) A step of heating a mixture of a binder, sugar alcohol and / or sugar, and optionally water, (c) The step of adding (i) caffeine, (ii) a combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) a combination of active ingredients including taurine, (d) A process for preparing an oral product as defined in any one of Clauses 1 to 24, comprising the step of solidifying the mixture obtained to obtain an oral product. 26. (i) Caffeine (ii) Ginseng, and (iii) Taurine, A combination of active ingredients including At least one binder, and A solid oral product comprising a sugar alcohol, or a sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar. 27. (i) Caffeine, (ii) at least one B vitamin selected from the group consisting of at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) Ginseng, a combination of active ingredients, At least one binder, and A chewable solid oral product comprising a sugar alcohol, or a sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar. 28. (i) Caffeine, (ii) A combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) Taurine, and (iv) A combination of active ingredients including vitamin C, At least one binder, and A chewable solid oral product comprising a sugar alcohol, or a sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar.
Claims
1. (i) Caffeine, (ii) A combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) Taurine, A combination of active ingredients, At least one binder, and A chewable solid oral product comprising a sugar alcohol, or a sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar.
2. The solid oral product according to claim 1, wherein the total amount of B vitamins contained in the combination is about 0.1% to about 5% by weight of the oral product.
3. The solid oral product according to claim 1 or 2, wherein the caffeine is present in an amount of about 0.1% to about 5% by weight of the oral product.
4. The solid oral product according to claim 1 or 2, wherein the taurine is present in an amount of about 0.01% to about 5% by weight of the oral product.
5. The solid oral product according to claim 1 or 2, wherein the caffeine and taurine are present in a weight ratio of about 5:1 to about 1:
1.
6. The solid oral product according to claim 1 or 2, wherein the caffeine and taurine are present in a weight ratio of about 3:1 or about 2:
1.
7. The solid oral product according to claim 1 or 2, wherein the total amount of caffeine and B vitamins is present in a weight ratio of about 1:1 to about 10:
1.
8. The solid oral product according to claim 1 or 2, wherein the total amount of taurine and B vitamins is present in a weight ratio of about 5:1 to about 1:1 or about 5:1 to about 1:
2.
9. The solid oral product according to claim 1 or 2, wherein the combination of active ingredients further comprises (iv) vitamin C, and optionally, the vitamin C is present in an amount of about 0.1% to about 5% by weight of the oral product.
10. The solid oral product according to claim 9, wherein the total amount of vitamin C and B vitamins is present in a weight ratio of about 1:1 to about 10:1 or about 1:1 to about 15:
1.
11. The solid oral product according to claim 1 or 2, wherein the combination of active ingredients further comprises (v) ginseng, and optionally, the ginseng is present in an amount of about 0.001% to about 0.1% by weight of the oral product.
12. The solid oral product according to claim 1 or 2, wherein the combination of the active ingredients further comprises (vi) vitamin D.
13. The solid oral product according to claim 1 or 2, wherein the oral product comprises a combination of active ingredients in an amount of about 0.5% to about 10% by weight of the oral product.
14. The solid oral product according to claim 1 or 2, further comprising one or more additives selected from the group consisting of flavoring agents, sweeteners, acidifying agents, fillers, wetting agents, preservatives, and mixtures thereof, preferably wherein the oral product comprises an acidifying agent.
15. The solid oral product according to claim 1 or 2, wherein the oral product further comprises zinc or zinc gluconate, and optionally, the zinc or zinc gluconate is present in an amount of about 0.001% to about 5% by weight of the oral product.
16. The solid oral product according to claim 1 or 2, wherein the oral product comprises at least one sugar alcohol.
17. The solid oral product according to claim 1 or 2, wherein the at least one sugar alcohol is selected from the group consisting of erythritol, arabitol, ribitol, isomalt, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, sorbitol, and combinations thereof, and optionally the at least one sugar alcohol is maltitol or contains maltitol.
18. The solid oral product according to claim 1 or 2, wherein the at least one sugar alcohol is present in an amount of about 40% to about 99% by weight of the oral product.
19. The solid oral product according to claim 1 or 2, wherein the oral product comprises at least one sugar alcohol including a combination of isomalt and maltitol, and optionally, the at least one sugar alcohol is present in an amount of about 50% to about 99% by weight of the oral product.
20. The solid oral product according to claim 1 or 2, wherein the oral product comprises a combination of at least one sugar alcohol and a sugar, and optionally the at least one sugar alcohol is maltitol or comprises maltitol.
21. The solid oral product according to claim 1 or 2, wherein the at least one binder is selected from the group consisting of cellulose derivatives, povidone, sodium alginate, starch-based binders, pectin, carrageenan, pullulan, zein, and combinations thereof, and optionally the at least one binder is pectin or contains pectin.
22. The solid oral product according to claim 1 or 2, wherein the at least one binder is present in an amount of about 0.001% to about 5% by weight of the oral product.
23. The solid oral product according to claim 1 or 2, wherein the oral product is in the form of a soluble tube.
24. (a) The steps of contacting at least one binder with at least one sugar, or at least one sugar alcohol, or a combination of at least one sugar and at least one sugar alcohol, and optionally adding water, (b) A step of heating a mixture of a binder, a sugar alcohol and / or sugar, and optionally water, (c) The step of adding (i) caffeine, (ii) a combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, and (iii) a combination of active ingredients including taurine, A process for preparing an oral product according to claim 1 or 2, comprising the step of (d) solidifying the obtained mixture to obtain an oral product.
25. (i) Caffeine, (ii) A combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, (iii) Ginseng, and (iv) Taurine, a combination of active ingredients, At least one binder, and A substance comprising a sugar alcohol, or a sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar, or (i) Caffeine, (ii) A combination of B vitamins including at least vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, (iii) Taurine, and (iv) Vitamin C, a combination of active ingredients, At least one binder, and A chewable solid oral product comprising a sugar alcohol, or a sugar, or at least one extender selected from the group consisting of a combination of at least one sugar alcohol and at least one sugar.
Citation Information
Patent Citations
Prescription of function form xylitol sugar-free chewing gum
CN101181003A
Oral composition for improving body small
JP1998245343A
Alcohol metabolism-enhancing beverages
JP2002530100A
Nutritional supplement containing ubiquinone
JP2004155778A
A combination of hydroxytyrosols to enhance mitochondrial function and energy production.
JP2012524033A
